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ABSTRACT
Mesenchymal stem cells (MSCs) can be isolated from bone marrow and 
can  differentiate  in  a  variety  of  cell  types,  including  osteoblasts, 
adipocytes, chondrocytes, myoblasts, hepatocytes, and neural cells. For 
this reason, MSCs are very promising for the development of cell-based 
therapy  for  degenerative  diseases.  Understanding  the  mechanisms 
behind MSC cell  fate  determination is  not  easy,  since the molecular 
processes that drive differentiation are complex and poorly understood. 
Even though in the recent years many improvements have been done, 
many mechanism need to be elucidated. We planned to investigate on 
differentiation mechanisms of MSC and, in particular, we focused our 
activities  towards  osteoblast  differentiation;  at  this  aim,  we  have 
silenced specific mRNAs using a mouse shRNA library in a 96 well plate-
based screening strategy. With this methodology we identified sevral 
genes  that  are  possible  candidates  for  a  role  in  osteoblast 
differentiation. 
Among the candidate genes, a consistent fraction was represented by 
genes whose function is still unknown: we focused our attention on a 
short number of these genes that we named ObI (Osteoblast inducer). 
In this thesis project we focused our experiments on a particular gene, 
that we named ObI-1. 
We also considered genes identified during the screening with a known 
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function  but  an  unknown  role  during  the  osteogenic  differentiation 
process. Among these genes we focused our attention on Angiotensin 
receptor 1 (AT1R), whose role in osteogenic differentiation had been 
previously suggested.
For both candidates that we analyzed for this project we confirmed the 
effects  of  silencing  on  osteogenic  differentiation  and  we  analyzed 
expression in tissues and in our cell culture system. Furthermore, we 
characterized function and mechanism of action in osteoblastogenesis 
for both genes.
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INTRODUCTION
1 - Adult stem cells
An adult stem cell is an undifferentiated cell, found in tissues or organs; 
this cell  type has the ability of renew itself and differentiate to yield 
some or all of the major specialized cell types of the resident tissues 
and organs. The primary role of adult stem cells in a living organism is 
to maintain and repair the tissue in which they are found. Adult stem 
cells have been identified in many organs and tissues, including brain, 
bone marrow,  peripheral  blood,  blood vessels,  skeletal  muscle,  skin, 
teeth, heart, gut, liver, ovarian epithelium, and testis. They are thought 
to reside in specific areas of each tissue, called "stem cell niches" (Li 
and Xie, 2005). Stem cells may remain quiescent for long periods of 
time until  they are activated by the need for more cells to maintain 
tissues,  or  by  diseases  or  tissue  injuries  (Walker  et  al.,  2009). 
Generally,  adult  stem cells  are thought to be able to develop into a 
limited number of  cell  types related to the resident tissue.  Typically, 
there is a very small  number of stem cells in each tissue, and once 
removed  from  the  body,  their  capacity  to  divide  is  limited,  making 
generation of large quantities of stem cells difficult. Research on adult 
stem cells has generated a great deal of excitement: if differentiation of 
adult  stem cells  can be controlled in the laboratory, these cells  may 
become the basis of transplantation-based therapies.
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1.2 - Adult stem cell differentiation
Adult stem cells can differentiate through normal pathways to form the 
specialized cell  types of  the tissue in which they reside or they can 
differentiate to other tissue from the cells  predicted lineage (Wagers 
and Weissman, 2004).
Normal differentiation pathways of adult stem cells. In a living animal, 
adult stem cells are able to divide, when needed, and can give rise to 
mature  cell  types  that  have  characteristic  shapes  and  specialized 
structures and functions of a particular tissue. 
Transdifferentiation. A  number  of  experiments  have  reported  that 
certain adult stem cell  types can differentiate into cell  types seen in 
organs or tissues other than those expected from the cells predicted 
lineage. This phenomenon is called transdifferentiation.
Although isolated instances of transdifferentiation have been observed 
in some vertebrate species, whether this phenomenon actually occurs in 
humans  is  under  debate  by  the  scientific  community.  Instead  of 
transdifferentiation,  the  observed  instances  may  involve  fusion  of  a 
donor cell with a recipient cell. Another possibility is that transplanted 
stem cells are secreting factors that encourage the recipient's own stem 
cells  to  proliferate  and  begin  the  repair  process.  Even  when 
transdifferentiation has been detected, only a very small percentage of 
cells appears to be able to undergo the process.
In  a  variation  of  transdifferentiation  experiments,  scientists  have 
recently  demonstrated  that  certain  adult  cell  types  can  be 
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"reprogrammed" into different cell types using a well-controlled process 
of genetic modification (Takahashi and Yamanaka, 2006). This strategy 
may offer a way to reprogram available cells into different cell types 
that have been lost or damaged due to diseases. 
In addition to reprogramming cells to differentiate into a specific cell 
type, it is now possible to reprogram adult somatic cells to acquire a 
pluripotent  state;  these  cells  have  been  demonstrated  induced 
pluripotent stem cells, (iPSCs) (Welstead et al., 2008). Thus, a source of 
pluripotent  cells  specific  to  the  donor,  (thereby  avoiding  issues  of 
histocompatibility) can be generated and used for tissue regeneration. 
However, like for embryonic stem cells, methods by which iPSCs can be 
completely and reproducibly committed to appropriate cell lineages are 
still under investigation.
2 - The bone marrow system
The bone marrow is a tissue found in the hollow interior of bones. This 
organ is composed of hematopoietic and the mesenchymal lineages: the 
first  give  rise  to  the  blood  cells  while  the  second  includes  non-
hematopoietic cells that can support hematopoiesis and mesenchymal 
stem cells  and  their  progeny,  such  as  osteocytes,  chondrocytes  and 
adipocytes (Fig. 1).
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2.1 - Bone marrow stromal cells
Bone marrow stromal cells, BMSCs, are a well-characterized population 
of adult stem cells. These cells can differentiate into a variety of cells, 
including adipocytes,  cartilage,  bone,  tendon and ligaments,  muscles 
cells, skin cells and even nerve cells.
Unlike most other human adult stem cells, BMSCs can be obtained in 
quantities that are suitable for clinical applications, making them good 
candidates for use in tissue engineering. Techniques for isolation and 
amplification  of  BMSCs  have  been  established  and  the  cells  can  be 
maintained  and  propagated  in  culture  for  long  periods  of  time, 
mantaining their capacity to form all the above cell types.
The  majority  of  culture  techniques  still  take  a  colony  forming  unit-
fibroblast,  CFU-f,  approach:  raw  unpurified  bone  marrow  or  ficoll-
purified  bone marrow monocytes  are  plated directly  into  cell  culture 
plates or flasks and BMSCs, but not red blood cells or haematopoetic 
progenitors, are adherent to tissue culture plastic within 24 to 48 hours 
(Friedenstein et al., 1966; Friedenstein et al., 1970; Owen et al., 1988). 
Other flow cytometry-based methods allow the sorting of bone marrow 
cells for specific surface markers. They are tipically negative for CD34, 
CD45, CD14, CD11b, Cd19, CD79a and HLA-DR and have been shown 
to pe positive for Stro-1, CD29, CD73, CD90, CD105, CD166, CD44 and 
CD133 (Dominici M et al., 2006).
Furthermore, BMSCs can be transduced, a phenomenon that could be 
exploited for the delivery of beneficial molecules to targeted locations.  
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Figure 1: The Bone marrow system
The bone marrow is the source of two distinct lineages, the haemtopoietic and the 
mesenchymal lineage. From he haematopoietic lineage derive blood cells; from the 
mesenchymal stem cells derive the supporting stromal cells, osteocytes, chondrocytes 
and adipocytes. Adapted from http://stemcells.nih.gov. 
Animal in vivo experiments aimed at reconstitution of damaged tissues 
such as cartilage, bone, muscle, heart muscle and tendon using BMSCs 
cells have shown great promises for clinical applications. 
2.1.1 - Differentiation Potential of BMSCs
The differentiation of BMSCs is influenced by convergence of intrinsic 
cellular  signals  and  extrinsic  micro-enviromental  cues  from  the 
surrounding stem-cell niche, but all the specific signals involved remain 
largely unknown (Watt et al., 2000).
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Niche-external signals: the external signals that control stem cell fate 
collectively  make  up  the  stem  cell  micro-environment,  or  niche.  A 
complex interplay of short- and long-range signals between stem cells, 
their differentiating daughters, and neighbouring cells are involved in 
niche  maintenance.  Soluble  factors,  cell-cell  interaction  and  cell-
extracellular matrix interaction seem to contribute to the self-renewal of 
different  type of  stem cells  (Watt  et  al.,  2000;  Moore  et  al.,  2006; 
Wilson et al.,  2006). The most important signals implicated in BMSC 
stemness maintenance are some cytokines such as leukaemia inhibitory 
factor, LIF (Jiang et al.,2002; Metcalf et al., 2003),  fibroblast growth 
factors,  FGFs  (Bianchi  et  al.,  2003;  Zaragosi  et  al.,  2006),  and 
mammalian homologues of  Drosophila  wingless,  Wnts (Boland et  al., 
2004; Ling et al., 2008 ).
Niche-intrinsic  signals:  intrinsic  regulators  of  self-renewal  include 
proteins  responsible  for  setting  up  cell  division,  nuclear  factors 
controlling  gene  expression,  chromosomal  modification  and  telomere 
length  (Watt  et  al.,  2000).  Embryonic  stem  cells  (ESCs)  maintain 
pluripotency  by  a  transcriptional  program  that  suppresses 
differentiation; this property is regulated by a small  number of ESCs 
specific  transcription  factors  such  as  Nanog,  Oct-4  Sox-2  and  Klf-4, 
whose expression is down-regulated early during embryogenesis (Boiani 
et  al,  2005).  In  the  last  years  several  groups  have  shown  the 
expression  of  Oct-4,  Nanog  and  Sox-2  in  the  most  undifferentiated 
BMSCs (Jiang et al., 2002; Beltrami et al., 2007).
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The identification of specific signalling networks and master regulatory 
genes that regulate BMSC differentiation in specific lineages remain a 
challenge.  Gene  repression  and  induction  may  be  main  mechanism 
involved in the maintenance of the niche (Quesenberry et al., 2002). 
Upon stimulation, multipotent uncommitted BMSCs undergo asymmetric 
division, giving rise to two daughter cells, one being exact replica of the 
mother cell and manintaining multilineage potential, and other daughter 
cell becoming a precursor cell, with a restricted developmental program 
(Quesenberry et al., 2002). To date, the mechanism that governs the 
transit of uncommitted stem cells to partially committed precursor or 
progenitor  cells,  and  then  to  fully  differentiated  cells  is  not  fully 
understood.
2.1.1.1 - Adipogenesis
The  nuclear  hormone  receptor  peroxisome  proliferation-activated 
receptor  gamma,  PPARγ,  is  a  critical  adipogenic  regulator  promoting 
BMSC adipogenesis while repressing osteogenesis (Rosen et al., 2006). 
The bipotent co-regulator TAZ was recently discovered to function as a 
coactivator of Runx2 and as a co-repressor of PPARγ, thus promoting 
osteogenesis while blocking adipogenesis (Hong et al., 2005). A similar 
role is played by Wnt signalling: the suppression of Wnt signalling is 
required for adipogenesis (Liu et al., 2004).
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2.1.1.2 - Chondrogenesis
Chondrogenic differentiation of BMSCs in vitro mimics that of cartilage 
development  in vivo. The transcription factor Sox-9 is considered the 
master gene of chondrogenesis and is responsible for the expression of 
extra  cellular  matrix  (ECM) genes such as collagen types II  and IX, 
aggrecan,  biglycan,  decorin  and  cartilage  oligomeric  matrix  protein 
(Goldring et al., 2006). However, the specific signaling pathways that 
induce  the  expression  of  these  chondrogenic  genes  remain  largely 
unknown. Naturally occurring human mutations and molecular genetic 
studies have identified several  relevant signaling molecules, including 
various  transforming  growth  factor  β  (TGF-β),  bone  morphogenetic 
protein (BMP) (Massague et al., 2000), growth and differentiation factor, 
GDF (Chen et al., 2004), and Wnt ligand (Hartmann et al., 2006).
2.1.1.3 - Osteogenesis
During osteogenesis, multipotent BMSCs undergo asymmetric division 
and  generate  osteoprecursors,  which  then  progress  to  form 
osteoprogenitors,  pre-osteoblasts,  functional  osteoblasts  and 
osteocytes.  This  progression  from  one  differentiation  stage  to  the 
following is accompanied by activation and subsequent inactivation of 
transcription factors and expression of bone related marker genes.
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3 - Osteogenic differentiation of BMSCs
In the osteogenic differentiation of BMSCs are involved a number of 
growth factors, the relative signaling pathways that they activate and a 
number  of  cellular  products,  especially  transcription  factors.  In  this 
section  are  described  some  of  the  most  important  growth  and 
transcription factors involved in osteogenesis (Fig. 2).
3.1 - Growth factors involved in osteoblast differentiation
3.1.1 - Bone Morphogenetic Proteins
BMPs  are  members  of  the  TGF-superfamily  of  polypeptides,  which 
includes TGF-s, activins,  and inhibins (Wozney JM et al,  1988); they 
were originally identified because of their ability to induce endochondral 
bone  formation.  BMP  proteins  display  extensive  conservation  among 
species having seven characteristic cysteine knot domains (Wang EA et 
al., 1990). The conserved cysteine domains participate in the formation 
of  an  interchain  disulfide  bond  between  two  monomers  to  form  a 
dimeric  precursor  protein.  The  precursor  dimers  are  secreted  as 
propeptides, which are activated by proprotein convertases (Cui Y et al., 
1998).
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Figure  2:  Signalling  and  transcription  factor  regulation  in  osteogenic 
differentiation
Wnt  and  BMP  pathway  induce  osteogenic  differentiation  through  the  up-
regulation of some osteo-specific transcription factors such as Runx2, Osterix, 
Dlx5 and Msx2.
To  date,  around  20  BMP  family  members  have  been  identified  and 
characterized. BMPs signal  explicates through serine/threonine kinase 
receptors, composed of type I and II subtypes. Three type I receptors 
have been shown to bind BMP ligands, type IA and IB receptors (BMPR-
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IA or ALK-3 and BMPR-IB or ALK-6) and type IA activin receptor (ActR-
IA or ALK-2) (Koenig et al., 1994; ten Dijke et al., 1994). Three type II 
receptors for BMPs have also been identified and they are type II BMP 
receptor (BMPR-II) and type II and IIB activin receptors (ActR-II and 
ActR-IIB)  (Yamashita  et  al.,  1995;  Rosenzweig  et  al.,  1995).  These 
receptors are differentially expressed in various tissues. Type I and II 
BMP  receptors  are  both  indispensable  for  signal  transduction.  After 
ligand binding they form a heterotetrameric-activated receptor complex 
consisting of two pairs of a type I and II receptor complex (Moustakas 
et  al.,  2002).  The type I  BMP receptor  substrates  include a  protein 
family, the SMAD proteins, that play a central role in relaying the BMP 
signal from the receptor to target genes in the nucleus. Smad1, 5 and 8 
are  phosphorylated  by BMP receptors  in  a  ligand-dependent  manner 
(Hoodless  et al.,  1996;  Chen  et al.,  1997). After phosphorylation they 
form a complex with Smad4 and then are translocated into the nucleus 
where they interact with other transcription factors. BMPs can activate 
Smad-indipendent pathway such as Ras/MAPK pathway (Attisano et al., 
2002;  Lai  et  al.,  2002).  BMP-2  activates  ERK and  p38  through  Ras 
kinase stimulation and, as result of this activation, ATF-2 and Fos/Jun 
protein are up-regulated and interact with activating protein-1, AP-1, 
sequences in the regulation of the expression of different genes. The 
activation  of  p38  is  essential  for  the  expression  of  BMP-2,  type  I 
collagen, osteocalcin, alkaline phosphatase and the activation  of p38 
and ERK is essential for the expression of fibronectin and ostepontin 
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(Lai  et  al.,  2002).  MAPKs  pathway  can  activate  different  pathways 
independently or in sinergistic way with SMAD (Attisano et al., 2002).
3.1.2 - BMP pathway in osteoblast differentiation
Although BMPs are synthesized by skeletal cells, their synthesis is not 
limited to bone because they are expressed by a variety of extraskeletal 
tissues  in  which  they  play  a  critical  role  in  development  and  cell 
function.  BMPs increase commitment of cultured marrow stromal cells 
to osteoblast phenotype by increasing CBFA1 mRNA expression (Lee et 
al., 2002; Ito et al., 2003). BMP-4 mRNA levels are BMP-dependent: in 
fact,  BMPs  cause  an  early,  short-lived,  induction  of  BMP-4 mRNA in 
osteoblasts  followed  by  an  inhibitory  effect,  suggesting  autocrine 
regulation  (Pereira  et  al.,  2000).  The  transient  increase  in  BMP-4 
expression induced by BMPs may be required to force cell progression 
toward a differentiated state, whereas the down-regulation suggests a 
local control mechanism. BMP-2 also can be up- and down-regulated by 
other  BMPs  in  osteoblasts,  and  it  is  of  interest  that  BMP-2  and  -4 
promoters contain Runx-2/Cbfa-1 binding sequences (Helvering et al., 
2000; Ghosh-Choudhury et al., 2001). This opens the possibility for a 
positive  feedback loop  regulating BMP-2 and  -4  expression  involving 
Runx-2/Cbfa-1  because  BMPs  induce  Runx-2/Cbfa-1  expression 
(Banerjee et al., 2001). In long-term cultures of osteoblasts, there is an 
increase in BMP-4 mRNA expression after cell maturation, which may be 
secondary to a larger pool of cells expressing Runx-2/Cbfa-1 (Chen et 
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al., 1997).
3.1.3 - Wnt pathway 
Wnt proteins act on target cells by binding to Frizzleds (Fzs), sevenspan 
transmembrane  receptor  proteins,  and  LRP-5/6,  single-span 
transmembrane  co-receptor  proteins.  The  canonical  Wnt  pathway 
affects cellular functions by regulating β-catenin levels and subcellular 
localization (Akiyama, 2000). The canonical Wnt pathway is initiated by 
the  binding  of  appropriate  Wnt  ligands  to  the  Fzs  and  LRP-5/6  co-
receptor.  In  absence  of  appropriate  Wnt  ligands,  β-catenin  is 
phosphorylated  and  polyubiquitinated  for  the  following  proteasome-
mediated degradation (Ikeda et  al.,  1998; Eastman et al.,  1999). In 
presence  of  an  appropriate  Wnt  ligand,  binding  of  Wnt  to  receptor 
complex leads to the activation of the intracellular protein, Dishevelled 
(Dvl),  that  inhibits  β-catenin  degradation  that  accumulates  and 
translocates to the nucleus, where in concert with members of the T cell 
factor/lymphoid  enhancer  factor  (TCF/LEF)  family,  activates  the 
transcription of a wide range of genes.
The Non-canonical Wnt pathway functions in a β-catenin independent 
manner  (Gordon  et  al.,  2006).  Non-canonical  Wnt  signals  are 
transduced through Fz family receptors and coreceptors, such as ROR2 
and RYK,  but  not LRP-5 or LRP-6 (Katoh et  al.,  2007).  This  binding 
mediates the signaling through G-protein,  protein  kinase C (PKC) or 
calcium/calmodulin-dependent  protein  kinase  II  (CamKII)  to  induce 
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nuclear factor of activated T cells (NF-AT) and other transcription factors 
(Wang et al., 2003; Kohn et al., 2005).  Taken together, although the 
specificity between Wnt molecules and Fz receptors remains unclear, it 
is known that different Wnt ligands will preferentially activate canonical 
or non-canonical Wnt pathways (Johnson et al., 2007).
3.1.4 - Wnt pathway in osteoblast differentiation
Members  of  the  Wnt  family  participate  and  play  a  central  role  in  a 
variety of fundamental processes during embryonic development, such 
as limb skeletogenesis (Yang et al., 2003). Wnt pathway also represents 
a  mechanism  in  mesenchymal  cells  proliferation  and  differentiation 
during chondrogenesis or osteogenesis. For example, Wnt-3a has been 
shown to promote proliferation and suppress osteogenic differentiation 
of adult MSCs (Boland et al., 2004), suggesting canonical Wnt signaling 
pathway functions in maintaining an undifferentiated, and proliferating 
progenitor  MSC  population.  Wnt  pathway  is  also  involved  in  BMPs-
mediated osteogenesis (Fischer et al., 2002; Chen et al., 2007) and is 
able to induce the osteoblastic transcription factors, Cbfa-1, Dlx-5, and 
Osterix.  These data strongly indicate that Wnt pathway is  intimately 
associated  with  bone  regenerative  process.  Two  microarray  gene 
expression studies in a rat closed fracture model revealed that several 
genes for  Wnt signaling components  and their  target  genes are up-
regulated (Hadjiargyrou et al., 2002; Zhong et al., 2006). These data 
indicate that  Wnt signaling pathway is  also activated during fracture 
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healing.
3.2  -  Transcription  factors  involved  in  osteoblast 
differentiation
3.2.1 - Runx2
Runt-related transcription factor (Runx)-2 or corebinding factor (Cbfa)-1 
plays a critical role in the differentiation of cells toward an osteoblastic 
pathway (Banerjee  et al.,  2001). Gene-targeted disruption of Runx-
2/Cbfa-1 results in disorganized chondrocyte maturation and a complete 
lack  of  bone  formation  due  to  an  arrest  of  osteoblast  development 
(Ducy et al., 1997;  Komori et al., 1997). Runx-2/Cbfa-1 also plays a 
role  in  mature  osteoblastic  function,  and  transgenic  animals 
overexpressing a dominant negative form of Runx-2/ Cbfa-1, under the 
control  of  the  osteoblastic  specific  osteocalcin  promoter,  display 
decreased bone formation due to impaired osteoblastic function (Ducy 
et al., 1999). This indicates a dual role of Runx-2/Cbfa-1 in cells of the 
osteoblastic  lineage,  regulating  osteoblastogenesis  as  well  as  the 
function  of  mature  osteoblasts.  The  role  of  Runx-2/Cbfa-1  in  later 
stages of differentiation is less clear, and its overexpression under the 
control of the type I collagen promoter results in osteopenia because of 
the lack of terminal maturation of osteoblastic cells (Liu et al., 2001). 
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3.2.2 - Osterix
Osterix is a zinc finger transcription factor expressed by osteoblasts and 
required  for  endochondral  and  intramembranous  bone  formation. 
Osterix-null mice have normal cartilage development but fail to develop 
a  mineralized  skeleton  (Nakashima  et  al.,  2002).  Osteoblast 
differentiation is arrested, and histological analysis reveals absence of 
trabecular bone. Osterix-null mice have reduced or absent expression of 
a  variety  of  bone  matrix  proteins,  including  type  I  collagen,  bone 
sialoprotein,  osteonectin,  osteopontin,  and  osteocalcin,  confirming  a 
role  in  the  induction  of  osteoblast  differentiation  and  function.  In 
contrast  to  Runx-2/Cbfa-1-null  mice  that  do  not  form  osteoblasts, 
osterix-null  mice  form  cells  of  the  osteoblastic  lineage  that  express 
Runx-2/Cbfa-1, but the cells do not mature. This would indicate that 
osterix  has  effects  on  skeletal  development  that  are  independent  of 
Runx-2/Cbfa-1 and that acts downstream of Runx-2/Cbfa-1 (Nakashima 
et al., 2002).
3.2.3 - Msh
The Msh family of homeobox genes includes Msx 1, 2, and 3. Msx 3 is 
expressed in  the central  nervous  system, whereas Msx 1 and 2 are 
expressed in skeletal tissue and modulate osteogenesis. Msx 1-null mice 
display  cleft  palate  and  craniofacial  and  dental  developmental 
abnormalities,  and Msx 2-null  mice have defects in skull  ossification, 
which are enhanced in double Msx 1/Msx 2 mutants (Satokata et al., 
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2000). Msx 2-null mice have defective chondrogenesis and osteogenesis 
due  to  a  decreased  number  of  osteoprogenitor  cells.  The  skeletal 
abnormalities are associated with decreased expression of Runx-2/Cbfa-
1,  indicating  that  Msx  2  is  necessary  for  osteogenesis  and  acts 
upstream of Runx-2/Cbfa-1. However Msx2 represses transcription of 
osteocalcin  directly  by  binding  the  promoter.  Because  osteocalcin  is 
expressed late in osteoblast differentiation and is potentially regulated 
by Msx2, this transcription factor may have role in both early and late 
differentiation events (Dodig et al., 1999).
3.2.4 - Dlx 5 
The mammalian homolog of  Drosophila  distalless (Dlx) 5 is homeobox 
genes essential for craniofacial and skeletal development (Robledo et 
al., 2002). Dlx 5 mRNA is expressed in osteoblasts after differentiation, 
concomitant with a decline in Msx 2 mRNA and with the appearance of 
osteocalcin  transcripts  (Ryoo  et  al.,  1997).  BMP  induces  Dlx  5 
expression  in  osteoblasts  and  overexpression  of  Dlx  5  induces  an 
increase of alkaline phosphatase activity, osteocalcin, and mineralization 
of  the  extracellular  matrix  (Miyama  et  al.,  1999).  Targeted  gene 
inactivation of Dlx 5 results in severe skeletal abnormalities but Runx2 
expression is unaltered (Robledo et al., 2002).
4 - Bone tissue
Bone, although strong, is a constantly changing tissue that has several 
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functions. Bones serve as rigid structures to the body and as shields to 
protect  delicate  internal  organs.  They  provide  housing  for  the  bone 
marrow, where the blood cells are formed and a point of attachment for 
skeletal muscles. Bones also maintain the body's reservoir of calcium 
and phosphate.
Bones have two shapes: flat, such as the plates of the skull and the 
vertebrae, and tubular, such as the thighbones and arm bones, which 
are called long bones. All bones have essentially the same structure. 
The hard outer part, cortical bone, consists largely of proteins, such as 
collagen,  and  a  substance  called  hydroxyapatite,  which  is  composed 
mainly  of  calcium  and  other  minerals.  Hydroxyapatite  is  largely 
responsible for the strength and density of bones. The inner part of 
bones, trabecular bone, is softer and less dense than the hard outer 
part. Bone marrow is the tissue that fills the spaces in the trabecular 
bone. Bone marrow contains specialized cells (including stem cells) that 
produce blood cells. Blood vessels supply blood to the bone, and nerves 
surround the bone.
Bones undergo a continuous process of remodeling. In this process, old 
bone tissue is gradually replaced by new bone tissue. Every bone in the 
body is completely reformed about every 10 years. To maintain bone 
density and strength, the body requires an adequate supply of calcium, 
other minerals, and vitamin D. 
Bones are covered by a thin membrane called the periosteum. Injury to 
bone  transmits  pain  because  of  nerves  located  mostly  in  the 
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periosteum.  Blood  enters  bones  through  blood  vessels  that  enter 
through the periosteum.
A characteristic of all connective tissues, including bone and cartilage, is 
that they contain a large amount of intercellular substance surrounding 
cells.  There  are  four  important  types  of  cells  associated  with  bone 
tissue: osteogenic cells, osteoblasts, osteocytes, and osteoclasts (Fig. 
3). 
• Osteogenic  cells  are  pre-osteoblast  cells  derived  from 
mesenchyme, which is the precursor for all forms of connective 
tissue.  When  osteogenic  cells  undergo  mitosis,  the  resulting 
daughter cells are called osteoblasts
• Osteoblasts  are fully  differentiated cells  that  cannot  reproduce. 
They are responsible  for  bone formation,  secreting the organic 
substances  and  mineral  salts  used  in  ossification  processes. 
Osteoblast possess receptors for hormone regulating bone growth
• Osteocytes  are  osteoblasts  that  have  become  isolated  in  the 
intercellular  substance  that  they  have  deposited  around 
themselves. They are cells that have stopped laying down new 
bone, but play a role in maintaning the cellular activities of bone 
tissue in their immediate area
• Osteoclasts  are  formed  by  the  fusion  of  monocytes  in  the 
endosteum. They are found on bone surfaces and function in bone 
resorption.  They  have  receptors  for  various  hormones  that 
regulate their activity
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Figure 3: Bone tissue cells
There are four main types of bone cells in bone tissue. Osteogenic cells respond to 
traumas, such as fractures, by giving rise to bone-forming cells. Osteoblasts (bone-
forming  cells)  synthesize  and  secrete  protein  and  matrix  important  for  the 
mineralization and are found in areas of high metabolism within the bone. Osteocytes 
are  mature  bone  cells  made  from  osteoblasts  that  have  bone  tissue  around 
themselves.  These  cells  maintain  healthy  bone  tissue  by  secreting  enzymes  and 
controlling the bone mineral content; they also control the calcium release from the 
bone tissue to the blood. Osteoclasts are large cells that break down bone tissue. They 
are very important to bone growth, healing, and remodeling.  
4.1 - Ossification
There are two kinds of bone formation: intramembranous ossification 
and  endochondral  ossification.  In  both  ossification  processes,  pre-
existing  connective  tissue  is  replaced  by  bone.  In  intramembranous 
ossification, some mesenchyme cells are transformed into osteoblasts 
and start laying down bone. 
This  is  an ossification process  that  transforms membrane into  bone. 
Additional bone is formed around the edge of this center until the entire 
membrane  is  ossified.  Intramembraneous  ossification  is  the  process 
used to make flat bones such as the mandible and flat bones of the 
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skull. In endochondral ossification, a hyaline cartilage model of the bone 
is replaced and ossified. This is the process associated with fetal bone 
development, day-to-day bone growth, and fracture repair. This is the 
type of bone formation found in the development of long bones such as 
the femur and humerus (Fig. 4).
5 - Bone related pathologies 
5.1 - Fractures
A fracture is a partial or complete break in continuity of the bone that 
occurs  under  mechanical  pressure.  Most  fractures  are  caused  by 
traumatic injury, however bone cancer or metabolic disorders can also 
cause fractures by weakening the bone. Fractures may result in loss of 
function  in  the  affected  limb,  guarded  movements,  pain,  soft  tissue 
swelling (edema), and deformity.
Fractures are classed anatomically, by the extent of the injury, or by the 
angle of the fracture.
5.1.1 - Fracture repair
There are four phases in fracture repair (Fig. 5):
Hematoma formation: when a bone breaks, the blood vessels in the 
bone, periosteum and surrounding tissues also break. This results in a 
mass of clotted blood, or hematoma, forming at fracture site
Fibrocartilaginous callus formation: capillaries grow into hematoma and 
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phagocytic  cells  consume  the  cellular  debris.  .Fibroblasts  and 
osteoblasts also migrate into the hematoma from the periosteum and 
endosteum and starts to produce cartilage. Some fibroblasts produce 
collagen  fibers  that  link  the  broken  bones  together,  while  some 
osteoblasts start producing spongy bone. The entire mass of soft tissue 
produced  is  called  fibrocartilaginous  callus  and  serves  to  split  the 
broken bone together.
                    
Figure 4: Endochondral ossification
Endochondral ossification begins in points in the cartilage called primary ossification 
centers. They mostly appear  during fetal  development, through a few short bones 
begin their primary ossification after birth. They are responsible for the formation of 
the  diaphyses  of  long  bones,  short  bones  and  certain  parts  of  irregular  bones. 
Secondary ossification occurs after birth, and forms the epiphyses of long bones and 
the extremities of irregular and flat bones. The diaphysis and both epiphyses of a long 
bone are separated by a growing zone of cartilage. 
Bone callus formation: osteoblasts and osteoclasts continue to migrate 
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into the fibrocartilaginous callus  and convert  the existing callus  to  a 
bone callus made up of spongy bone.
5.2 - Osteoporosis
Osteoporosis  refers  to  a  set  of  diseases  in  which  bone  resorption 
overwhelms bone formation. Normal bone mass becomes reduced, and 
bones become more porous, weaker, and lighter. Osteoporosis usually 
affects the spongy bone of the spine, leading to compression fractures 
between   vertebrae.  The  head  of  the  femur  also  often  fractures  in 
people with osteoporosis.
Estrogen acts to inhibit osteoclasts activity, and when estrogen levels 
decrease, osteoclasts activity increases to erode the bone matrix. Other 
factors contributing to osteoporosis can include: an inactive lifestyle, a 
diet low in calcium and protein, or as consequences of other diseases 
such as hyperthyroidism.
5.3 - Osteoarthritis
Osteoarthritis, or degenerative joint disease, is the most common form 
of chronic arthritis. In this disease, the articular cartilade degenerates 
and  bone  grows  into  the  joint  space.  As  the  joint  space decreases, 
movement becomes more difficult and painful. Osteoarthritis occurs as 
a consequence of aging and “wear and tear” on a joint over the years
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Figure 5: Physiology and process of facture healing
After  the bone fracture, there are four major phases of  bone tissue healing: 
formation of fracture hematoma, fibrocartilaginous callus formation, bony callus 
formation and bone remodelling.
6 - High-throughput screening
High-Throughput  Screening  (HTS)  allow  to  quickly  conduct  large 
numbers of biochemical, genetic or pharmalogical tests. Through these 
processes it is possible identify active compounds, antibodies or genes 
which modulate a particular biomolecular pathway. The results of these 
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experiments provide starting points for understanding the interaction or 
role of a particular biochemical process in biology and for drug design. 
Essentially, HTS uses automation to perform screenings of a particular 
assay against a library of candidate compounds. 
An assay is a test for a specific activity such as inhibition or stimulation 
of a biochemical or biological mechanism. The key labwares for HTS are 
microplates which generally have 384, 1536 or 3456 wells; these are all 
multiple of 96 well plates. Each well contains a specific compound to 
test. After the test, it is necessary manual or automated analysis  of 
results.
Automation  is  an  important  element  in  HTS  utility.  Typically,  an 
integrated robot system transports assay microplates from station to 
station for sample and reagent addition, mixing, incubation, and finally 
read out or detection. An HTS system can usually prepare, incubate and 
analyze many plates simultaneously; currently HTS robots can test up 
to 100,000 compounds per day. 
Occasionally,  HTS  cannot  be  completely  automated:  in  this  case  an 
operator need to perform the assay for the candidates compounds. The 
difference  between  automated  and  non  automated  system  depends 
upon the type and the complexity of the screening.
6.1  -  High-throughput  screening  with  RNA  interference-
based approach
A classic example of activity used by HTS is gene silencing with RNA 
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interference  technique.  In  fact,  many  libraries  of  RNA  interference 
molecules validated for their sequence and acting versus most of the 
genome sequence of human and mice are available.
Target sequences are selected on the basis of thermodynamic criteria in 
order to reach a strong silencing efficiency.
Loss  of  function  phenotypes  are  often  the  key  to  understand  the 
function  of  genes  involved  in  biological  processes:  in  this  case  RNA 
interference technique is used to identify the role of a gene towards its 
silencing.
Recently, a lot of research groups focused their activity on this type of 
approach:  many  scientific  articles  refer  about  the  use  of  high-
throughput screening to investigate about a specific biological process. 
There are many studies about the investigation of genes functioning in a 
specific  cellular  processes  in  mammalian  cells:  One  example  is  the 
research  of  several  genes  involved  in  mammalian  cell  cycle  using  a 
strategy based on RNA-interference (Kittler et al., 2008). Furthermore, 
HTS  had  been  applied  also  in  other  system  such  as  Drosophila 
Melanogaster to  find  genes  involved  in  development  (Perrimon  and 
Mathey-Prevot, 2007).
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7 - RNA-Interference
7.1 - Biological functions and effectors
RNA interference (RNAi) is a form of post-transcriptional gene silencing 
mediated  by  a  little  double-strand  molecule  of  RNA (dsRNA,  double 
strand RNA) capable of block messenger RNA target molecules that will 
not be able to be translated.
This  is  a  natural  process  preserved  during  the  evolution  and  it  is 
involved in several mechanisms:
• Protection against genome instability
• Defence against viral attacks
• Gene expression regulation
• Developmental regulation
RNA interference can be activated by a double strand of RNA brought 
into the cell (siRNA, small interfering RNA) that leads to the degradation 
of mRNA target. RNA interference can be also activated by small non 
codifying transcripts synthesized within the cell (miRNAs, micro RNA): 
in  this  case  not  always  the  mRNA  target  is  degradated  through 
cleavage.
Main effectors of RNA interference process are:
miRNA  :  miRNA are short single-strand molecules of RNA of about 20-22 
nucleotides  with  a  5’P  Cap  and  2  nucleotides  3’  protruding.  Their 
biogenesis starts in the nucleus: their corresponding genes are located 
in the intergenic regions and in transcriptional units both in the sense 
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and  anti-sense  orientation  (Lagos-Quintana  et  al.,  2001;  Lau  et  al., 
2001; Maurelatos et al. 2002). 
miRNA are first synthesized as primary miRNA (pri-miRNA) containing 
the  5’  Cap  and  a  polyadenilation  sequence  at  3’;  then  they  are 
processed by Drosha RNA polymerase III that generates molecules of 
70-80 nucleotides  with  a  stem and loop  structure,  precursor  miRNA 
(pre-miRNA). Pre-miRNA are translocated from nucleus to cytoplasm by 
a complex of receptors on the nuclear membrane, such as exportin5 
(Lund et al., 2004; Bohnsack et al., 2004).
Pre-miRNA are processed in miRNA by Dicer, a ribonucleasic enzyme of 
the  RNA  polymerase  III  family  with  two  catalytic  domains  and  one 
dsRNA-binding domain. Each miRNA binds the enzymatic complex RISC 
(RNA-interference silencing complex), forming a RNA-protein complex 
named miRISC (Fig. 6).
Small  RNA  molecules  are  then  separated:  the  sense  strand  is 
degradated while the antisense strand is drove toward the mRNA target 
by a RISC complex subunit, Argonauta 2 (Ago2) (Liu et al., 2004). If 
miRNA  and  mRNA target  strands  are  highly  complementary,  RNA is 
cleaved; otherwise they are partly mismatched, RISC complex linked to 
mRNA does not allow the normal ribosomes translation. In both cases 
no protein is made.
siRNA:  siRNA  are  short  molecules  of  double-strand  RNA  of  21-23 
nucleotides  with  two  phosphate  groups  at  5’  and  2  nucleotides  3’ 
protruding generated bt Dicer. They can be introduced  into the cells by 
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both transfection and infection. 
The antisense strand binds the RISC complex forming the RNA-protein 
complex siRISC which recognize the mRNA target and cleave it (Fig. 7).
shRNA: short hairpin RNA (shRNA) are small RNAs with a stem and loop 
structure: they mimic the pre-miRNA structure and so follow their same 
processing. shRNA are expressed by plasmids or viral vectors and for 
this reason they present the advantage to perform a stable silencing of 
their mRNA targets.
7.2 - Off-target effects
Off-target  effects  are  defined  as  the  consequences  of  not  desired 
interactions  between  RNA  interference  molecules  and  cellular 
components or no target mRNA.
7.2.1 - Sequence-independent effects 
Among  the  sequence-independent  effects  there  are  transfection 
conditions and inhibition of the endogenous activity of miRNA. miRNA 
endogenous  activity  inhibition  may be  provoked  by  RNA-interference 
machinery saturation: an example is the saturation of the exportin5 (Yi 
et a., 2005).
7.2.2 - Sequence-depended effects
Among  the  sequence-depended  effects  there  are  immune  response 
stimulation  and  interaction  with  no  mRNA  targets.  The  immune 
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response can be provoked by type I interferons when siRNA are longer 
than 30 base pair. Another mechanism is the recognition of single- or 
double-strand RNA molecules by Toll-like receptors (TLRs) which leads 
the inflammatory response towards NFkB, IRF and ATF2 transcription 
factors in the nucleus. 
It is possible to reduce the interferon-mediated response avoiding the 
presence of some nucleotids motifs, such as GU traits, in the small RNA 
sequences (Judge et al., 2005). The main reason of sequence-depended 
off target effects is however the interaction between RNA-interference 
effectors and no target mRNA. To avoid this problem is important verify 
that a RNA-interference molecule has the minimal omology with other 
mRNA sequences other than its mRNA target. 
Two solution for  this  problem are redundancy and phenotype rescue 
experiments (Fig. 8). In the redundancy experiments are used different 
effectors having the same mRNA target: in this way, probability that 
two distinct RNA molecules share the same off-target effects is minor. 
In the phenotype rescue experiments it is used a functional version of 
the target gene resistant to RNA-interference effector (Echeverri et al., 
2006).
39
Figure 6: Functional model of the miRISC complex in human
miRNA are transcripted by RNA polymerase II in primary miRNA (pri-miRNA) of 60-
100 nucleotids.  Pri-miRNAs are  cleaved by Drosha to  form precursor miRNA (pre-
miRNA) of  60-70 nucleotids  containing 2 nucleotids  3’  protruding.  Pre-miRNAs are 
traslocated  into  cytplasm  by  exportin5-RanGTP  complex  and  by  other  adapter 
proteins.  In  cytoplasm,  pre-miRNA  are  processed  in  short  molecules  (~22-  nt), 
miRNAs, by Dicer. After, miRNA bind protein complex RISC containing several known 
proteins  such  as  AGO2,  AGO1,  Dicer,  TRBP  e  RCK  and  unknown  proteins.  RISC 
complex drive antisense strand towards mRNA target.
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Figure 7: Functional model of the siRISC complex in human
Long  double  strand  RNA  or  hairpin  RNA  are  cleaved  by  Dicer  into  short 
interfering  RNA  molecules  of  21-nucleotids  (siRNAs)  with  2  nucleotids  3’ 
protruding and a phosphate group at 5’. Alternatively, siRNAs can be introduced 
into the cells where are phosporilated at 5’ by cellular kinases. These small RNA 
assembled  into  RISC  complex  that  contains  AGO2,  Dicer  and  other  cellular 
factors. RISC find mRNA target which is cleaved with the possible recycle of the 
RISC complex for several cleavage events.
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Figure 8: Experimental controls to minimize off-targets effects in i-RNA 
experiments
In redundancy experiment two RNA intreference molecules acting against two 
different regions of the same target are used. In phenotype rescue experiment a 
resistant version of the mRNA target is used.
8  -  Zinc-finger  transcription  factors  containing  the 
Kr ppel-associated box familyȕ
The largest family of zinc-finger transcription factors comprises those 
containing the Kr ppel-associated box (KRAB-containing proteins): theyȕ  
were first discovered almost 30 years ago (Bellefroid et al. 1991) and 
represent  the  largest  single  family  of  transcriptional  regulators  in 
mammals. Many genes encoding KRAB-containing proteins are arranged 
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in  clusters,  but  other  occurs  individually  across  the  genome.  Their 
structure consist in different domains with a range that can change in 
the different proteins (Urrutia, 2003) (Fig. 9). The main domains are: 
KRAB domain located near the N-terminus of the protein which act as a 
strong transcriptional repressor (Witzgall et al., 1994), and various zinc-
finger domains at C-terminus which bind DNA (Looman et al., 2002).
The most remarkable feature of the KRAB-containing proteins is that 
they are present only in vertebrate genomes (Urrutia, 2003). The KRAB 
domain  is  present  in  the  sequences  of  zinc-finger  proteins  in  the 
human, mouse, rat, chicken and frog genomes while is absent in fish, 
Drosophila, plants, yeast and other fungi: this distribution suggest that 
the presence of KRAB domain is relatively recent in the evolution. The 
functions  known  for  the  members  of  this  protein  family  include 
transcriptional repression of RNA polymerase I, II and III promoters and 
binding and splicing of RNA; however, functions of most of the proteins 
of this family have not been completely studied.
An example of study on one of these proteins was the characterization 
of  a  novel  zinc-finger  transcription factor containing a  KRAB domain 
involved  in  bone  development  (Jheon  et  al.,  2001).  This  study 
demonstrated the capacity of this factor to modulate Runx2 activity and 
osteogenic differentiation. 
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Figure 9: Primary structures of typical KRAB-containing zinc-finger proteins
Different proteins of  this family  contain different  range of functional domains.  The 
number of zinc fingers vary form 4 to over 34 (for semplicity here are shown only 8 
for each structure). The KRAB domain consist of the A and B boxes. Some members of 
the  family  have  a  leucine-rich  SCAN  domain  that  allows  homo-  and  hetero-
dimerization with other SCAN-containing zinc-finger proteins. 
9 – Renin-Angiotensin System: Overview
 
9.1 - The Circulating Renin-Angiotensin System 
Angiotensin  belongs  to  renin-angiotensin  system  (RAS),  that  is 
important in regulating blood pressure, sodium homeostasis and fluid 
balance (Hall  JE,  2003).  The discovery  of  a  metabolic  pathway that 
contributed a major role to circulatory homeostasis was made in the 
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1950's (Braun-Mendez E et al., 1940; Page IH et al,1940; Cleland SJ et 
al., 1997). In the circulating RAS, a decrease in renal perfusion pressure 
stimulates the production and release of renin, a proteolytic enzyme, 
from the juxta-glomerular cells of the kidney into the circulation. Renin 
cleaves angiotensinogen,  a circulating α2-globulin synthesised by the 
liver,  to  form  the  decapeptide  angiotensin-I.  Angiotensin-converting 
enzyme (ACE), which is found both as a membrane bound protein at the 
cell  surface  and  in  circulating  plasma  (soluble  ACE),  subsequently 
further cleaves angiotensin-I to form the octapeptide Ang-II (Lavoie JL 
et  al.,2003).  Ang-II  exerts  several  effects  including  salt  and  water 
retention via the release of aldosterone from the adrenal cortex, and 
vasoconstriction (Cleland SJ et al., 1997). Moreover, another important 
role of ACE is in the degradation and inactivation of BK, which otherwise 
has  potent  vasodilatory  effects  and  influences  muscle  metabolism. 
Finally,  Ang-II  can  be  further  degraded  to  form  angiotensin  III, 
angiotensin IV and angiotensin-(1-7). These biologically active peptides 
may  contribute  some  of  the  effects  of  RAS,  although  their  relative 
contribution is unclear (Campbell DJ, 2003).
9.2 - Angiotensin-II Receptors 
Ang-II produces its effects via two main receptors, type I (AT1) and 
type II (AT2), which were originally classified according to their ability 
to bind with various ligands antagonists (Murphy et al, 1991; Mukoyama 
M et  al,  1993; De Gaspero M et  al,2000).  More recently,  two other 
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angiotensin II receptors (AT3 and AT4) have been described, but their 
role has yet to be clearly defined. AT1 and AT2 receptors are both seven 
transmembrane  domain  G-protein  coupled  receptors,  although  they 
appear to have quite different pharmacology.
 
Figure 10: Summary of the Renin-Angiotensin System 
Angiotensin is an oligopeptide that causes blood vessels constriction. It is derived from 
the  precursor  molecule  angiotensinogen,  a  serum  globulin  produced  in  the  liver. 
Angiotensin I is formed by the action of renin on angiotensinogen. Renin is produced 
in  the  kidneys  in  response  to  decreased  intra-renal  blood  pressure  at  the 
juxtaglomerular cells. Angiotensin Converting Enzyme (ACE) catalyses the production 
of angiotensin II from angiotensin I. 
The  AT1  receptor  is  expressed  ubiquitously  and  appears  to  mediate 
most of the well known biological effects of Ang-II. In contrast, the role 
of  the  AT2  receptor  is  less  well  understood.  Although  it  is  highly 
expressed  in  foetal  tissues  during  development,  its  expression 
decreases  markedly  after  birth.  However,  the  AT2  receptor  can  be 
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upregulated in pathological conditions, for example after injury, during 
wound healing and by ischaemia (De Gaspero M et al,2000). It appears 
to have an opposing role to the AT1 receptor, antagonising its actions. 
Angiotensin receptor elicits its responses predominantly via G-protein. 
Ang  II  stimulates  PLC  through  Gαq  coupled  to  AT1  receptor  and 
subsequently  the  formation  of  DAG and  IP3,  that  activate  PKC  and 
release  of  Ca2+ from the  sarcoplasmic  reticulum (Hunyady L  et  al, 
2006).  AT2  receptor  is  coupled  to  Gαi and  subsequently  to  several 
phosphatases including tyrosine and Ser/Thr phosphatases (Nouet S et 
al., 2000). Angiotensin receptor can also be stimulated by G protein-
indipendent  signal  transduction  mechanism.  Recent  studies 
demonstrated  that  several  scaffold  protein  can  organize  signalling 
complexes  for  the  activation  of  MAPKs,  ERKs  and  JNKs  pathway 
(Prossnitz ER, 2004; Thomas WG et al., 2003). In cardiac fibroblast and 
the kidney Ang II-induced  AT1r activation also stimulates the Jak/STAT 
pathway (Booz GW et al., 2002).
47
Figure 11: Putative model of signal mechanisms induced by angiotensin II 
(Ang II) 
AP-1,  activator  protein-1;  ATx,  angiotensin  II  receptor  subtype;  CaM,  calmodulin; 
DAG,  diacylglycerol;  IP3,  inositol-1,4,5-triphosphate;  JAK,  janus  kinase;  MAPK, 
mitogen-activated protein kinase; MKK,  MAPK kinase; MKKK,  MAPK kinase kinase; 
MKP-1, MAPK phosphatase-1; NF-AT3, nuclear factor of activated T-cells 3; NF-κ B, 
nuclear factor κ B; NO, nitric oxide; PKC, protein kinase C; PLC, phospholipase C; 
PP2A, protein phosphatase 2A; PTK, protein tyrosine kinase; PTPase, protein tyrosine 
phosphatase; SH-PTP1, Src homology domain-containing protein tyrosine phosphatase 
1; STAT, signal transducer and activator of transcription.
9.3 - The Local Renin-Angiotensin Systems
In addition to the circulating RAS, local RAS have also been described in 
various tissues including the heart, brain, lung, pancreas and adipose 
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tissue (Jones A et al,2003; Izu Y et al, 2009). A local RAS has now been 
discovered in skeletal muscle (Dragovic T et al.,1996; Schaufelberger M 
et al, 1998). This local skeletal muscle RAS depends on a combination 
of in-situ synthesis of all the RAS components and the uptake of renin 
or pro-renin from the circulation (Danser AH et al, 2003). ACE has been 
identified on both skeletal muscle membranes and on endothelial cells 
of the capillary bed (Dragovic T et al.,1996;  Schaufelberger M et al, 
1998). Osteoblasts and osteoclasts have been demonstrated to express 
angiotensin  receptors  1  and  2  (AT1R  and  AT2R,  respectively)  and, 
recently, involvement of the RAS in osteoporosis development has been 
demonstrated (Shimizu H et al, 2008; Asaba Y et al, 2009); in addition, 
AT2R blockade has been shown to increase bone mass (Izu Y et  al, 
2009).  Angiotensin  II  (Ang  II)  treatment  of  osteoblast  seems  to 
indirectly stimulate osteoclasts proliferation through expression of the 
receptor activator of NF-kb ligand (RANKL) (Shimizu H et al,  2008); 
however, results regarding the use of AT1R inhibitor are controversial 
(Izu Y et al, 2009; Shimizu H et al, 2009, Broulik PD et al, 2001). On 
the other hand, inhibition of RAS blocks primary calvaria osteoblasts 
differentiation and mineral deposition in vitro (Hagiwara H et al, 1998). 
The  role  of  this  local  RAS  is  still  debated  but  may  include  growth 
stimulation, neovascularisation, and the regulation of inflammation (Igic 
R et al, 2003). The importance of tissue RAS as a potential therapeutic 
target  comes  from evidence that  the  anti-hypertensive  properties  of 
ACE inhibitors correlate better with the inhibition of tissue ACE, rather 
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than plasma ACE. Furthermore, the additional benefits of ACE inhibitors 
such as improved endothelial  function and reduction in inflammation, 
appear to be independent of changes in blood pressure, and are thought 
to relate to effects  on local  RAS systems (Dzau VJ  et  al,  2001). In 
addition, AT1R inhibitors, such as losartan, have been effective in the 
treatment of Marfan syndrome, a disease due to mutation in the fibrillin 
I gene that leads to an excess of TGF-beta signaling (Hagiwara H et al, 
1998; Brooke BS et al, 2008; Cohn RD et al, 2007; -25); TGF-beta had 
been previously identified as one of the genes involved in mesenchymal 
cell proliferation and in mesenchymal progenitors commitment (Roelen 
BA et al, 2003).
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MATERIALS AND METHODS
10 - MATERIALS
10.1 - Mouse shRNA library
shRNA library consist in 64,000 bacterial stocks containing plasmid DNA 
expressing   shRNA  constructs  that  cover  the  entire  mouse 
transcriptome. Bacterial stock are stored in single wells in 96 well plates 
in glycerol stock at -80°C (Fig 11).
               
Figure 11: Images of a mouse shRNA library plate
Bacterial stock of the shRNA library are stored in single wells in 96 well plate (left 
side). Library plates have an ID number and a bar-code to identify the specific plates 
for each shRNA construct (right side).
10.1.1 - Bacterial cells
PirPlus (Pir-1)-competent bacteria (Open Biosystems). It’s a Escherichia 
Coli stock expressing the pir1 gene.
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10.1.2 - Plasmid DNA
pSM2 (pShag Magic  Version 2.0;  Open Biosystems) retroviral  vector. 
This plasmid contains the following features: 1) Murine Stem Cell Virus 
(MSCV) backbone with Retroviral Signaling Sequences; 2) U6 promoter; 
3) RK6γ conditional origin of replication. Requires the expression of pir1 
gene  within  the  bacterial  host  to  propagate;  4)  Kanamycine  and 
Chloramphenicol   resistance  as  bacterial  selection  markers;  5) 
Puromycine  resistance  for  selection  after  transfection  in  mammalian 
cells . 6) Sequence that express the shRNA construct (only sequence 
difference between all the plasmids (Fig 12). 
                
Figure 12: pShag Magic Version 2.0 features
Structure of the DNA plasmids contained within bacterial stocks of the mouse shRNA 
library. Each plasmid contain a DNA segment for the expression of a specific DNA 
construct. Furthermore, plasmids contain several common features.
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10.2 - Cell cultures
10.2.1 - Culture of cell lines
W20-17  cells  were  obtained  from  ATCC  (American  Type  Culture 
Collection). Cells were cultured in Dulbecco’s Modified Eagle’s Medium, 
High Glucose (D-MEM) (Euro Clone) supplemented with 10% selected 
Fetal  Bovine Serum (FBS) (HyClone) and 2mM L-Glutammine (Gibco, 
Invitrogen).
10.2.2 - Culture of murine bone marrow stromal cells 
Murine  Bone  Marrow  Stromal  Cells  (mBMSC)  were  obtained  by 
isolation from mouse tibias in our laboratory (Esposito et al.,  2009). 
Cells  were  cultured  in  alpha  minimum  essential  medium  (α-MEM) 
(Cambrex Bio Science) supplemented with 10% selected Fetal Bovine 
Serum (FBS) (HyClone) and 2mM L-Glutammine (Gibco, Invitrogen).
10.3 - Differentiation media
10.3.1 - Osteogenic medium
D-MEM supplemented with 10% selected FBS, 2mM L-Glutammine, 0.05 
mM  ascorbic  acid  2-phosphate  (Sigma  Aldrich),  10  mM  β-
glicerolphosphate  (Sigma Aldrich),  5  x  10-3 M dexametasone (Sigma 
Aldrich). Angiotensin II (Sigma, St. Louis, MO US), PD123319 (Sigma, 
St. Louis, MO US) and losartan potassium (Fluka, St. Louis, MO US) was 
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added  to  the  medium every  day  accordingly  with  the  differentiation 
protocol.
10.3.2 - Adipogenic medium
D-MEM  supplemented  with  10%  selected  FBS,  2mM  L-Glutammine, 
5µg/mL insulin (Sigma Aldrich), 0,5 µM isobutylmethylxanthine (IBMX) 
(Sigma Aldrich), 50 µM indometacin (Sigma Aldrich).
10.4 - Solutions
10.4.1 - Trypsin/EDTA
0.2 % Trypsin (Invitrogen),  1% chicken serum (Euro Clone),  10 mM 
EDTA (pH=8).
10.4.2 - Formalin 10%
Cells fixing solution. 10% Formaldehyde (Sigma Aldrich), 90% Water.
10.4.3 - Alizarin Red S
2%  Solution (2 g Alizarin Red S powder per 100 mL water). pH = 4.1-
4.3.
10.4.4 - Solutions for ALP staining
Fixing solution:
Neutral Formalin Buffer (NFB) 10% (+4°C).
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Staining solution:
Naphtol AS MX-PO4 powder (0.005 g) in DMF (N,N-Dimethylformamide) 
(200 µL).
Tris-HCl (MW = 157.6) 0.2 M, pH 8.3 (25 mL) + distilled water (25 mL).
Red Violet LB salt (0.03 g)
Note: Prepare (a) and (b) separately; add (a) + (b); add (c). 
10.4.5 - Oil Red
0.5% solution (0.5 g Oil red-O per 100 mL water).
10.4.6 - Guanidine HCl
Used for Alizarin Red S staining quantitation; it was prepared at 4M. 
11 - METODS
11.1 - Transfection with LipofectamineTM 2000
Transfection  with  LipofectamineTM 2000  (Invitrogen)  was  performed 
following the procedure’s guidelines. Initially, cells were plated in the 
plastic support and allowed to growth overnight to reach the confluence 
of  70%-80% optimal  for  the  transfection.  The  day  after,  cells  were 
transfected  with  different  DNA:  DNA  and  Lipofectamine  2000  were 
separately diluted in D-MEM without serum and incubated for 5 minutes 
at room temperature (the amount of the dilution medium and of DNA 
and lipofectamine depends upon the plastic support used). After the 5 
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minutes  incubation  the  diluted  Lipofectamine  and  diluted  DNA  were 
combined,  mixed  gently  and  incubated  for  20  minutes  at  room 
temperature. Finally the reagent/DNA mixture was added to the plated 
cells after the change of the medium in which they were. After 6 hours, 
medium with  the  mixture  was  removed  and  replaced  with  standard 
medium.
In the table 1 are reported volumes of medium and quantities of DNA 
and reagent used in our experiment in 96 and 6 well plates (Tab. 1).
CULTURE 
VESSEL
SURFACE 
AREA PER 
WELL
VOLUME OF 
PLATING 
MEDIUM
VOLUME OF 
DILUITION 
MEDIUM
DNA LIPOFECTAMINETM 
2000
96 well 0,3 cm2 100 µL 2 x 25 µL 0,2 
µg
0,5 µL
6 well 10 cm2 2 mL 2 x 250 µL 4,0 
µg
10 µL
Table 1: Quantity of components for DNA transfection in 96 and 6 well plates
Note: For DNA transfection in 96 well  plates during the screening a gene reporter 
plasmid was co-transfected at concentration of 70-100 ng per well in order to evaluate 
the efficiency of the transfection after 24-48 hours. 
11.2 - Puromycin selection
Cells transfected with shRNA plasmids of the library were cultured for 3 
days in medium supplemented with puromycin in order to enrich cell 
population that incorporated the plasmid DNA. Puromycin amount was 
established on the basis of puromycin kill-curve experiments on cells for 
3 days: for  W20-17 the concentration of puromyicin used is  2.0-2.5 
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µg/mL.
11.3 - Differentiation assay
11.3.1 - Osteogenic differentiation
Cells are cultured for 21 days with osteogenic medium (section 10.3.1) 
at 37°C in humidified atmosphere at 5% CO2. Osteogenic medium is 
replaced every 3-4 days.
11.3.2 - Adipogenic differentiation
Cells are cultured for 14 days with adipogenic medium (section 10.3.2) 
at 37°C in humidified atmosphere at 5% CO2. Adipogenic medium is 
replaced every 3-4 days.
11.4 - Staining assay 
11.4.1 -  Alizarin Red staining 
Cells  were washed with PBS and fixed in 10% formaldheyde for 1h; 
after rinsing with distilled water they were incubated with Alizarin Red S 
2% solution (section 10.4.3) with gentle agitation for 10 min. Excess 
staining was removed using PBS.
11.4.2 - ALP staining
Cells were washed with cold PBS and fixed with 10% cold NFB (section 
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10.4.4)  for  15  min.  Cell  were  incubated  with  the  staining  solution 
(section 10.4.4)  for  15 min and then were washed 3-4 times using 
distilled water. 
11.4.3 - Oil Red staining
Cells were washed with PBS and fixed in 10% formaldehyde for 15 min; 
after rinsing with distilled water, they were incubated with Oil  Red-O 
working  solution  (section  10.4.5)  for  10  min.  Excess  staining  was 
removed using PBS and cells  were then counter-stained hematoxylin 
(Bio-Optica) for 3 min and washed with distilled water. 
11.5 – Staining Quantitation assay
11.5.1 -  Alizarin Red staining quantitation 
Alizarin Red S solution bound to the calcium deposits  was extracted 
using over-night incubation with Guanidine HCl 4M (10.4.6) at room 
temperature. Absorbance at 490 nm of the resulting supernatant was 
used for quantitative calcium determination.
11.5.2 - Alkaline phosphatase assay 
The cells were washed twice with Tyrode's balanced salt solution (50mM 
Tris-HCl pH 7.4, 0.15M sodium chloride) and then incubated with 5mM 
p-nitrophenylphosphate in 50mM glycine, 1mM magnesium chloride pH 
10.5 at 37°C for 5 to 20min. The reaction was stopped by adding 3M 
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sodium hydroxide to each well. Optical density (OD) was measured at 
405nm.
11.5.3 - Oil Red staining quantitation 
The lipid bound dye was extracted using isopropanol incubation for 15 
min at  room temperature.  Quantitative assessment  was  obtained  by 
measuring adsorbance of the extracted dye at  550nm.
11.6 - Proliferation assays
W20-17 cells  were seeded in 96 microwell  plates and cultured for 4 
days in osteogenic differentiation media. Then cells were washed with 
PBS and cultured with regular media for 48 h. The proliferation was 
assessed with  CellTiter 96 AQueous Non-Radioactive assay (Promega, 
Madison, WI US) in according to manufacturer’s  instructions and the 
absorbance measured at 490nm.
11.7 - RNA extraction
TriReagent (Sigma Aldrich) was used in order to extract RNA from the 
cells. 1 mL of TriReagent was added to the cells (1 mL per each well of a 
six well plate in our experiments) after aspirating culture medium and 
washing with  PBS.  After  addition  of  the  reagent  the  cell  lysate  was 
passed several times through pipette to form an homogenous lysate. 
After homogenization, the homogenate was centrifuged at 12,000 g for 
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10 minutes at 4°C. Following the centrifuge the clean supernatant was 
transferred to a fresh tube and left for 5 minutes at room temperature. 
After,  0.2 ml  of  chloroform was added per  1 ml  of  TriReagent  used 
initially. The sample was shook vigorously for 15 seconds and allowed to 
stand  for  2-15 minutes  at  room temperature,  resulting  mixture  was 
centrifuged at 12,000 g for 15 minutes at 4°C.
After  centrifugation  the  upper  aqueous  phase  containing  RNA  was 
transferred in a fresh tube, mixed with 1/10 of isopropanol, left for 5 
minutes  at  room  temperature  and  centrifuged  at  12,000  g  for  10 
minutes. Subsequently, the supernatant was transferred to a fresh tube 
and the RNA was precipitated by adding 0.5 ml of isopropanol per 1 ml 
of TriReagent used in sample preparation. The sample was allowed to 
stand  for  5-10  minutes  at  room  temperature  and  then  it  was 
centrifuged  again  at  12,000  g  for  10  minutes  at  4°C.  After  this 
centrifugation the supernatant was removed and the RNA pellet washed 
by adding 1 ml of 75% ethanol per 1 ml of TriReagent used initially; the 
sample was centrifuged at 7,500 g for 5 minutes at 4°C. Finally, the 
supernatant was removed, the RNA pellet dried for 5-10 minutes by air-
drying and risuspended in an appropriate volume of water.
11.8 - RT PCR
2 µg of RNA extracted was added to random nanomers, dNTP mix and 
water (until 16 µL of final volume). Mix was incubated at 70° for 10 min 
and then in ice for 1 min. After that, were added Reverse transcriptase 
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buffer (1X) RNAsi inhibitor and M-MuLV Reverse Transcriptase enzyme 
(New England BioLabs) (final volume: 20 µL). Program for reaction was: 
42° for 1 h and 90° for 10 min.
11.9 - Real-Time PCR 
Real-Time  PCR  was  performed  with  LightCycler  machine  using  Sybr 
Green as probe. PCR program for each cycle as: 50° for 2 min, 95° for 
10 min, 95° for 15 sec, 60° for 1 min, 95° for 15 sec, 60° dor 15 sec. 
Control is represented by GAPDH determination. 
11.10 - Western Blot
Total  cell  lysates were obtained by treatment with lysis  buffer (1mM 
EDTA  ,  50  mM  Tris-HCl,  pH  7.5,  70  mM  NaCl,  1%  Triton  X-100), 
proteinase inhibitors (Complete Protease Inhibitor Cocktail, Roche) and 
phosphatase inhibitors (sodium fluoride 5mM and sodium orthovanadate 
1mM). Protein extracts were run on 10% SDS-PAGE gels, transferred on 
Immuno-Blot  PVDF  membranes  (Bio-Rad)  and  analyzed  using  the 
following  antibodies:  Phospho-Smad2/3  (Cell  Signaling,  Danvers,  MA 
US), Smad2/3 (Cell  Signaling, Danvers, MA US), Phospho-Smad1,5,8 
(Cell Signaling, Danvers, MA US), Smad1,5,8 (Cell Signaling, Danvers, 
MA US), Anti-Flag (Cell Signaling, Danvers, MA US), Anti-GAPDH (Cell 
Signaling, Danvers, MA US) and secondary HRP-conjugated antibodies 
(Amersham Bioscience, Uppsala, Sweden). The membrane was detected 
by chemiluminescence (ECL plus, GE Healthcare)
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11.11 - Immunofluorescence
Cells were fixed in 4% paraformaldheyde and permeabilized with 0.2% 
TX-100, 10% normal fetal bovine serum/1% bovine serum albumin in 
PBS for 30 min at room temperature. The samples were incubated with 
primary murine antibody anti-Flag (1:250) and then with an anti-mouse 
immunoglobulin G conjugated with Alexa Fluor 488 (Moleculare Probes, 
Eugene).  Images  were  captured  using  an  inverted  microscope 
(DMI4000, Leica Microsystem).
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RESULTS
12 - Components and experimental conditions set up
12.1 - Mouse shRNA library amplification
Bacterial  stock  containing  shRNA  plasmids  have  been  inoculated  to 
amplify the mouse shRNA library. The entire procedure of amplification 
has been automated using Biomek FX robot from Beckman (Fig. 13). 
Bacterial  stock  were  stored  in  96  well  plates,  and  our  plasmid 
preparations were performed in the same support. In this way we have 
been able to directly transfect all the plasmids in W20-17 cells seeded in 
96-well plate. 
To date 15,000 construct  have been amplified, corresponding to 150 
plates of the library. All the plates were catalogued in order to know the 
exact plate and well position for each construct.
Figure 13: Biomeck FX Robot from Beckman
Biomek FX Robot used to perform automated mini-prep procedure of the bacterial stock of the 
library.
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12.2 - In-vitro osteogenic differentiation 
In order to differentiate W20-17 cells into osteoblasts, we treated them 
for 21 days with osteogenic medium or D.A.G. medium (Dexametasone, 
Ascorbic Acid-2P and β-Glicerophosphate). Treatment of mesenchymal 
precursors  with  this  medium allows  to  obtain  a  good  differentiation 
since these reagents act as osteogenic differentiation inducers.
In  order  to  evaluate  completion  of  osteogenic  differentiation  we 
performed  an  Alizarin  Red  S  staining:  cells  differentiated  into 
osteoblasts form calcium deposits which are stained in red and are well 
visible at microscope analysis. We also included in our experiment cells 
treated with normal medium as negative control (Fig. 14).
We  also  quantify  Alizarin  Red  S  staining  using  4M  Guanidine-HCl 
extraction and absorbance reading at 490nm.
  
Figure 14: Osteogenic differentiation of W20-17 cell line
Alizarin Red S staining of W20-17 cells cultured in either the presence or absence of osteogenic 
medium. Cells not cultured with osteogenic medium were grown with normal medium. 
In order to further analyze the osteogenic differentiation process in our 
cells,  we performed a  time course  with  staining  and quantitation  of 
Alizarin Red adsorbance cells at different time points from day 0 until 
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day 21. We choose day 5, 7, 9, 12, 14, 16, 18 and 21 as different time 
points and we grew cells  in osteogenic and normal medium. For the 
cells grown in osteogenic medium, Alizarin Red S staining positivity is 
evident starting from day 12 with a gradual increase until day 21. On 
the contrary, cells grown in normal medium do not show positivity to 
Alizarin Red S staining for any of the time points considered (Fig. 15A). 
Microscope analysis of stained cells was confirmed by quantitation of 
staining: in fact, there is an increase of absorbance at 490 nm in the 
wells  containing  cells  treated  with  osteogenic  medium,  while  the 
absorbance remains constant in the wells containing cells treated with 
normal medium (Fig. 15B).
12.3 - W20-17 cell line characterization 
In order to characterize W20-17 cells differentiation into osteoblasts we 
evaluated the expression of several osteoegenic marker genes along the 
entire process; this analysis was necessary to demonstrate the effective 
changes at molecular levels during differentiation. At this purpose, we 
evaluated the expression of RunX2 and Osterix, as early markers, and 
Osteocalcin and Osteopontin, as late markers, at different time points: 
T0, T4, T14 and T21.
RunX2 expression has a bimodal curve: it increases from day 0 to day 
4, then it decreases at day 14 to increase again at the last time point 
(Fig. 16A). On the other hand, Osteopontin levels increase steadily from 
day  0  to  day  21  (Fig.  16B).  Osterix  and  Osteocalcin  present  an 
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expression pattern similar to Osteopontin, with a very high pick at day 
21 (Fig. 16C and 16D).
Figure 15:  Osteogenic differentiation time course of W20-17 cell line
Alizarin Red S staining of W20-17 cells cultured in normal and osteogenic medium at days 5, 7, 9, 
12,  14,  16,  18  and  21  (A).  Calcium  deposition  quantitation  using  Guanidine  HCl  4M  and 
adsorbance reading at 490 nm (B).
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12.4 - Experimental approach validation
Prior to the screening we verified our experimental approach and tested 
the functionality of shRNA constructs of the library in the inhibition of 
the differentiation process.  We prepared a 96-well  plate with several 
plasmids expressing shRNA constructs against genes previously shown 
to be involved in the osteogenic differentiation process. We chose about 
40 genes with  64 corresponding constructs. Among these genes we 
included  transcription  factors,  such  as  Runx2  and  Osterix,  growth 
factors,  such  as  BMPs  and  FGFs,  cellular  regulators,  such  as  SMAD 
protein and also differentiation markers such as osteocalcin and genes 
codifying for matrix proteins such as collagen.
We transfected W20-17 cells with the 64 constructs in a 96-well plate 
and proceeded with puromycin enrichment for three days in order to 
obtain a larger number of cells containing the library plasmids. 
After puromycin treatment we continued with osteogenic differentiation 
for 21 days and, finally, we performed Alizarin Red S staining and its 
quantitation with Guanidine HCl 4M (Fig. 17). 
In  this  experiment  we chose several  controls:  positive  and negative 
controls  of  differentiation,  respectively  represented  by  untransfected 
cells grown in osteogenic and normal medium, and a scrambled control 
for the RNA-interference technique, achieved using a library construct 
codifying for an shRNA that does not interfere with any known gene, 
shRNA Non Silencing (shRNA-NS). For this experiment we also chose 
several  controls  to  use  during  the  screening,  obtained  using  shRNA 
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constructs that interfere with genes whose role in osteogenic 
Figure 16: Expression analyses of osteogenic differentiation markers during osteogenic 
differentiation of W20-17 cells.
Expression profiles of Runx2 (A), Osteopontin (B), Osterix (C) and Osteocalcin (D) at days 0, 4, 
14 and 21 of differentiation of W20-17 cells. Data are means ± SD of 3 experiments.
differentiation is well  demonstrated. Following Alizarin Red S staining 
after 21 days of osteogenic differentiation, results were variable: 
for  some  genes  we  did  not  obtain  any  osteogenic  differentiation 
impairment,  while  for  other  genes  we  obtained  different  levels  of 
silencing,  in  some  cases  similar  to  the  negative  control  of 
differentiation.
Cells transfected with the shRNA-NS showed staining result similar to 
those  obtained  for  the  positive  control  of  differentiation.  Finally,  for 
constructs interfering with genes with a demonstrated role in osteogenic 
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differentiation we obtained different  levels  of  Alizarin  Red S staining 
impairment.  We  reported  staining  and  relative  quantitation  for  the 
negative and positive control of osteogenic differentiation; furthermore, 
we reported the staining for cells transfected with the shRNA-NS and 
cells transfected with shRNA interfering with Smad5 and Bmp1 genes as 
best examples of genes involved in the osteogenic differentiation which 
silencing produced effects in our experiment (Fig. 18A and 18B). Library 
constructs that interfere with these two genes were chosen as control 
for the screening.
Figure 17: Experimental approach to perform the screening
Cells  are  plated  in  96  well-plates  and  transfected  after  one  day  with  shRNA plasmids. Co-
transfection  with  a  plasmid  for  the  expression  of  a  reporter  gene  is  performed  to  supervise 
transfection efficiency. Then, cells are cultured for 2-3 days in presence of puromycin in order to 
enrich  cellular  population  that  incorporated  the  shRNA plasmids.  Finally,  cells  are  cultured  in 
osteogenic medium to differentiate into osteoblasts. 
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13 - Screening
13.1 - Transfection of shRNA mouse library
To date we have transfected about 10,000 constructs of the library in 
single wells and we collected the relative results. We acquired pictures 
of  plates  after  staining  and  of  the  specific  wells  with  the  most 
interesting results. Collection of the pictures, together with the 
Figure 18: Experimental approach validation
Alizarin Red S staining  after 21 days of:  1) untransfected W20-17 cells cultured in osteogenic 
medium; 2) untransfected W20-17 cells cultured in normal medium; 3) W20-17 cells transfected 
with shRNA Non Silencing and cultured in osteogenic medium; 4) W20-17 cells transfected with 
shRNA-SMAD5 and  cultured  in  osteogenic  medium;  5)  W20-17  cells  transfected  with  shRNA-
BMP1 and cultured in osteogenic medium (A). Calcium deposition was quantified using Guanidine 
HCl 4M and reading the adsorbance at 490 nm (B). Data are means ± SD of 3 experiments. 
collection of the data corresponding to the quantitation of the staining, 
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was  crucial  to  catalogue  and  record  all  the  results  of  the  screening 
(Fig.19).
Quantitation of the staining was very important to select a pool of most 
relevant candidate genes: in fact, we established a threshold of the OD 
sample/OD positive control of differentiation value and on the basis of 
this value we were able to further consolidate our results.
Up to now we have identified 650 candidate genes that correspond to 
6.5% on the total number of the screened genes.
Figure 19: Representative image of a plate after Alizarin Red S staining
This is a representative image of a plate as example of our screening results. Several wells don’t 
show red staining: genes silenced in these wells are putative candidates of our screening.
13.2 - Analysis of candidate genes
We started with an in-silico analysis of our results using bioinformatic 
tools to obtain a Gene Ontology classification of the candidate genes 
(Carmona-Saez  et  al.,  2007).  We found candidate genes  involved in 
signal transduction, transcription, transport within and between the cells 
and in developmental processes (Fig. 20).
It  was  interesting  to  find  candidate  genes  belonging  to  the  same 
pathway, such as apoptosis: this result further validate our screening 
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system (Fig. 21). A remarkable result of Gene Ontology analysis was to 
find a consistent fraction of genes with unknown function corresponding 
to the 30% of all the candidates identified in the screening. These genes 
belong to the Riken collection. In particular we focused our attention on 
a short number of these genes and we named them ObI- that stands for 
Osteoblasts inducers-. These genes were were chosen on the basis of 
their  putative  function:  in  fact,  bioinformatic  analysis  of  the  chosen 
genes predicted that they were transcription factors. 
We also considered  several genes identified during the screening wiht a 
known  function  but  an  unknown  role  during  the  osteogenic 
differentiation process. Among these candidates we mainly focused on 
angiotensin receptor gene.
Figure 20: Gene Ontology classification of candidates genes
Results of Gene Ontology classification of the candidate genes arose from the first  part of our 
screening. Biological processes represented by more than 3% of our candidates are shown in the 
graphic. 
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Figure 21: Identification of a pathway involved in osteoblast differentiation (Apoptosis).
Several gene of the apoptosis pathway were identified as candidate genes of our screening. Genes 
that are necessary for osteoblast development (i.e., absence of mineral deposit after silencing of 
these specific genes) are indicated with a star. 
14 - ObI-1 candidate gene
14.1 - Interference with osteogenic differentiation
Among the candidate genes with unknown function, interference with 
ObI-1 gene with corresponding shRNA construct of the library produced 
an almost total absence of Alizarin Red S staining in comparison to the 
positive control of differentiation. Furthermore, the effect seems to be 
specific of the action of the shRNA construct since transfection with the 
shRNA-NS produced the same effect of positive control of differentiation 
(Fig. 22). 
After  the  result  obtained  from  the  screening,  we  repeated  the 
interference experiments to confirm our data. We found two additional 
shRNA constructs interfering with ObI-1 and tested them in our system. 
Results obtained with all three constructs showed a significant reduction 
of  osteogenic  differentiation  (Fig.  23A  and  23B).  To  validate  the 
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specificity of the result achieved by the silencing, transcript levels of 
ObI-1 gene was evaluated by Real Time PCR analysis. In ObI-1 silenced 
cells, with all three constructs, the levels of transcript were extremely 
reduced compared to untransfected cells and Non-Silencing transfected 
cells.  These  results  confirmed  that  the  shRNAs  were  specifically 
silencing the W20-17.
Figure 22: ObI-1 results from the screening
Alizarin  Red  S  staining  after  culture  in  osteogenic  medium  for  21  days  of:  1)  W20-17  cells 
transfected with shRNA-ObI-1; 2) untransfected W20-17 cells;  3) W20-17 cells transfected with 
shRNA  Non  Silencing  (A).  Calcium  deposition  quantitation  using  Guanidine  HCl  4M  and 
adsorbance reading at 490 nm (B). Data are means ± SD of 3 experiments. 
74
Figure 23: Confirmation of screening results on ObI-1 
Alizarin  Red  S  staining  after  culture  in  osteogenic  medium  for  21  days  of:  1)  W20-17  cells 
transfected with shRNA-ObI-1#1 (shRNA construct used during the screening); 2-3) W20-17 cells 
transfected with shRNA-ObI-1#2 and shRNA-ObI-1#3 (other two library constructs acting against 
ObI-1 gene); 4) W20-17 cells transfected with shRNA-Non Silencing; 5) Untransfected cells (A). 
Calcium deposition quantitation using Guanidine HCl 4M and adsorbance reading at 490 nm (B). 
Data are means ± SD of 3 experiments.
75
14.2 - Protein domains and phylogenetic analyses 
Prior to an experimental analysis of the role of ObI-1, we proceeded 
with  an  in-silico  analysis  in  order  to  understand  its  structure  and 
function. Analysis on EnsEmbl database showed two transcripts for ObI-
1: a long and a short form (Fig 24A). Analysis of the protein revealed 
the presence of a KRAB and several zinc-finger domains for the long 
form; the short form contained only the KRAB domain (Fig. 24B). A 
phylogenetic analysis of ObI-1 gene was also performed on the EnsEmbl 
database. We found orthologue genes in many species: among these, 
we found the correspondent Human (Homo sapiens), Macaque (Macaca 
mulatta), Gorilla (Gorilla gorilla), Rat (Rattus norvegicus) and Cow (Bos 
Taurus) orthologues. 
In total, 14 orthologue genes were present but only the Human and Rat 
genes correspond to demonstrated proteins while in other species their 
presence is only predicted. 
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Figure 24: Transcripts and proteins domains of ObI-1 gene 
Bionformatic analysis to search for transcripts of ObI-1 gene: two different transcripts are evident, a 
long  and a short form (A). Bioinformatic analysis to search for functional domains in the ObI-1 
protein: long form present a KRAB domain and several Zinc finger domains, short form present 
only a KRAB domain (B).
14.3 - Expression analyses 
14.3.1 - Expression analysis in tissues
We first performed an in-silico analysis of the expression of ObI-1 in 
different tissues. Consulting UniGene database of NCBI (National Centry 
of Biotechnology Information) we looked for EST profiles and we found 
the presence of ObI-1 in different tissues at different levels (Fig 25).
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Figure 25: In silico analysis of ObI-1 expression in tissues
EST profile of ObI-1 transcript in mouse tissues 
(http://www.ncbi.nlm.nih.gov/UniGene/ESTProfileViewer.cgi?uglist=Mm.36612).
After  bioinformatic  analysis,  we  also  performed  Real-Time  PCR 
experiments to directly  evaluate the expression of  ObI-1 in different 
mouse tissues (Fig. 26).
Figure 26: ObI-1 expression in tissues
Expression profile of ObI-1 transcript in different tissues isolated form mouse.
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14.3.2 - Expression analysis in W20-17
Expression analysis of ObI-1 gene in W20-17 cell line was performed to 
evaluate  the  presence  of  its  transcripts  during  osteogenic 
differentiation. We analyzed the presence of both Obi-1 transcripts, with 
Real-Time PCR experiments at different time-points (T0, corresponding 
to the undifferentiated cells, and T4, T14 and T21). The levels of the 
long form of ObI-1 increase at day 4 of differentiation and they remain 
high during all the process. The levels of the short form are very low, 
therefore they might not have a significant role (Fig. 27). 
Figure 27: Expression analysis of ObI-1 during osteogenic differentiation of W20-17
Expression profile of ObI-1 transcripts during osteogenic differentiation of W20-17 cells at day 0, 4, 
14 and 21. Data are means ± SD of 3 experiments. *p<0.05 (respect to T0).
14.3.3 - Expression analysis in primary cells
After analysis  in W20-17 cell  line,  we also performed the expression 
analysis  of  ObI-1  gene  in  primary  murine  mesenchymal  stem  cells 
(mMSC). Also in this case we analyzed the presence of ObI-1 transcript 
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by Real-Time PCR during osteogenic differentiation. 
We  considered  three  different  time  points:  T0,  corresponding  to 
undifferentiated cells, and T3 and T21. As previously observed during 
osteogenic differentiation of W20-17 cells, we detected an increase of 
ObI-1 transcript levels in osteogenic differentiation of primary mMSC: 
ObI-1 expression rose at day 4 and further increased at day 21 (Fig. 
28).
In addition to these data we also performed expression analysis of ObI-
1  during  adipogenic  differentiation  of  MSC.  We  considered  three 
different  time  points:  undifferentiated  cells  (T0)  and  other  two  time 
points corresponding to day 3 (T3) and day 14 (T14). In this case we 
did  not  detect  any  increase  of  ObI-1  transcript  levels  during 
differentiation, but rather a decrease of the expression at day 14 (Fig. 
29).
Figure 28: Expression analysis of ObI-1 during osteogenic differentiation of mMSC
Expression profile of ObI-1 transcript during osteogenic differentiation of mMSC cells at day 0, 3 
and 21. Data are means ± SD of 3 experiments. 
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Figure 29: Expression analysis of ObI-1 during adipogenic differentiation of mMSC
Expression profile of ObI-1 transcript during adipogenic differentiation of mMSC cells at day 0, 3 
and 14.
14.4 - Sub cellular localization analysis
In order to check for the sub-cellular  localization of the protein product 
of the ObI-1 gene we cloned the cDNA of ObI-1 in pcDNA3 (Invitrogen) 
with a Flag. We first evaluated the expression of ObI-1 gene by Western 
Blot  analysis  comparing  protein  lysates  obtained  from W20-17  cells 
transfected with the pcDNA3 plasmid with or without the ObI-1 cDNA 
insert (Fig. 30).
After this experiment we performed Immuno-fluorescence analysis to 
find  the  sub-cellular  localization  of  ObI-1.  Merge  between  the  cells 
treated  with  DAPI  and  Anti-Flag  antibody  indicate  the  nuclear 
localization of ObI-1 gene (Fig. 31). 
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Figure 30: Detection of pCDNA ObI-1-Flag by Western Blot analysis
Protein lysate of cells transfected with pcDNA3 ObI-1 dual-Flag and not of cells transfected only 
with pcDNA3 was positive to anti-Flag antibody.  GAPDH was used as control  for each protein 
loading.
Figure 31: Detection of ObI-1 sub-cellular localization by immunofluorescence analysis
Expression of pcDNA3 ObI-1-confirm the nuclear localization of Obi-1. pcDNA3 expression was 
used as control.
14.5  -  Expression  profile  of  osteoblast  differentiation 
markers in ObI-1 silenced cells
To investigate  the  role  of  ObI-1 during osteogenic  differentiation we 
evaluated, by Real  Time, the expression profile of some of the early 
82
differentiation markers  in  untransfected cells  and in  cells  transfected 
with  either  ShObI-1  or  ShNS.  The  transcript  level  of  Runx2  and 
osteopontin  (OPN)  were  significantly  reduced  in  ObI-1  silenced  cells 
while,  in  cells  transfecetd  with  ShNS,  the  transcript  level  was 
comparable to untransfected cells (Fig. 31).
Figure 32: Effect of ObI-1 silencing on bone differentiation marker
Expression profile of early differentiation markers in ObI-1 silenced cells. Effect of ObI-1 silencing 
on bone differentiation marker. Runx2 and osteopontin results decreased in ObI-1 silenced cells.
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15 – Angiotensin receptor 1 candidate gene
15.1 - Interference with osteogenic differentiation
Silencing  of  Angiotensin  receptor  1  gene  (AT1R)  produced  a  strong 
impairment of the osteogenic differentiation of W20-17 cells.  Alizarin 
Red S staining of cells transfected with an shRNA interfering with AT1R 
expression showed a reduced mineralization at day 21 of differentiation. 
Cells  transfected  with  the  shRNA-NS  show  a  phenotype  similar  to 
untransfected cells.
We also analyzed a second shRNA-AT1R construct from our library that 
reproduced the same effect. We were able to demonstrate and confirm 
the  same  inhibition  effect  on  osteogenic  differentiation  for  both  the 
shRNA-AT1R constructs. In order to validate the specificity of the result 
of silencing, the level of AT1R protein was evaluated by Western blot 
analysis. In AT1R silenced cells the level of protein is extremely reduced 
compared  to  untransfected  cells  and  Non-Silencing  transfected  cells. 
Taken together this results were suggesting that AT1R gene may have a 
role in differentiation process.
15.1.1 - Effects of angiotensin receptor antagonist on 
osteoblast differentiation
In order to confirm the results obtained with shRNA-mediated silencing, 
we  differentiated  the  cells  in  presence  of  losartan,  a  specific  AT1R 
inhibitor, and PD123,319, a specific AT2R inhibitor. Losartan was able to 
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inhibit  W20-17  differentiation  at  a  very  low  concentration,  thereby 
confirming a specific  effect.  Same concentrations of PD123,319 were 
not able to inhibit this process, confirming the involvement of type-1 
receptor.
Figure 33: AT1R results from the screening
Alizarin Red S staining of  cells transfected with the constructs against AT1r gene, with a Non-
Silencing construct (ShNS) and non transfected cells (A). Quantification of Alizarin Red S staining 
of silenced and non silenced cells using Guanidine HCl 4M and adsorbance reading at 490 nm (B). 
Protein expression of AT1R in silenced and not silenced cells was evaluated by western blot (C). 
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Figure 34: Effects of angiotensin receptor antagonist on osteoblast differentiation
Inhibition of mineralization of osteoblastic cells in response to angiotensin receptor antagonists. 
Alizarin  Red S  staining  of  cell  treated  with  osteogenic  medium and  selective  AT1r  antagonist 
(Losartan [10-7M]). A selective AT2r antagonist (PD123,319 [10-7M]) was used as control to test 
the specificity of the involvement of AT1r during osteogenic differentiation (A).  Quantification of 
Alizarin Red S staining of treated cells (B). 
86
15.2 - Expression analysis in W20-17 cell line
We confirmed the presence of the angiotensin receptors transcript in 
our in-vitro differentiation system. At this purpose we performed a Real-
Time PCR experiment to evaluate presence and possible variations of 
AT1R transcript levels during osteogenic differentiation of W20-17 cells.
We  considered  four  different  time  points  during  the  process:  T0, 
corresponding to the undifferentiated cells, T4, T14 and T21. AT1R is 
expressed  at  low  levels  in  undifferentiated  cells  but  increases 
immediately  during  the  first  days  and  remaining  at  similar  levels 
throughout the process; conversely, AT2R expression increased during 
differentiation peaking only at the very end of the process.
Figure 34: Expression profile of angiotensin receptor during osteogenic differentiation 
Expression analysis of distinct AT1R and AT2R subtypes during the differentiation. 
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15.3  -  Study  of  the  role  of  AT1R  in  osteogenic 
differentiation
15.3.1 - Effect of AT1R inhibition on alkaline phospatase 
To  identify  whether  AT1R  was  involved  only  in  the  latter 
mineralization phase, we analyzed ALP expression and activity in 
W20-17 cells after 14 days of treatment with osteogenic media. 
W20-17 cells treated with losartan showed a reduced ALP staining 
compared to cells treated only with osteogenic medium. Analysis 
of  ALP  activity  confirmed  the  observation,  showing  that  cells 
treated  with  losartan  had  values  similar  to  W20-17  kept  in 
absence of osteogenic stimuli. These data therefore confirmed that 
AT1R  was  not  involved  only  in  the  mineralization  phase,  but 
differentiation  and/or  proliferation  were  dependent  by  the 
expression of this gene.
15.3.2  -  Time  course  analysis  of  the  AT1R  stimulation 
during the differentiation    
In order to further characterize the phase of the differentiation process 
where AT1R stimulation was more relevant, a time course experiment 
was performed starting to add losartan and PD123,319 at different time 
point (0, 7, 14 days) from the beginning of the differentiation. At any 
time of administration, PD123,319 treated cells showed an osteogenic 
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differentiation comparable with untreated W20-17. On the other end, 
Figure 35: Effects of angiotensin receptor antagonist on ALP expression
Inhibition of ALP expression in response to angiotensin receptor antagonists.  ALP staining (A) and 
activity (B) of cell  treated with osteogenic medium and selective AT1r antagonist (Losartan [10-
7M]).
Figure 36: The effects of angiotensin receptor I inhibitor are time-dependent 
The activation of angiotensin receptor I is essential for osteoblastic differentiation only in the first 
part of the process. The administration of losartan the osteoblastic mineralization only when its 
administration starts in the first week of the differentiation.
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losartan-treated  cells  showed  a  significant  reduction  of  alizarin  red 
staining only when losartan was added at  timepoint 0; on the other 
hand, W20-17 produced an almost completed mineralized matrix when 
losartan  was  added  later.  These  results  are  compatible  with  an 
involvement of AT1R in the very early phases of differentiation when we 
observed the most abundant increase of the transcript.
15.3.3 - Evaluation of AT1R stimulation on cell proliferation
We therefore decided to analyze Ang II effect on stimulation of pre-
osteoblast,  administering  different  doses  of  recombinant  protein  to 
W20-17 cells differentiating in osteogenic medium. Addition of Ang II to 
the  cells,  after  3  days  of  treatment  with  differentiation  media, 
significantly increased proliferation in a dose-dependent manner; this 
effect could be reversed by the addition of losartan, whereas addition of 
PD123,319 did not affect proliferation at this stage. A proliferative effect 
of Ang II was also observed in undifferentiated W20-17 and primary 
mesenchymal stem cells (MSCs) although was not comparable to what 
observed in differentiating cells. It's probably due to the low expression 
of AT1R in completely undifferentiated cells
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Figure  37:  Angiotensin  II  has  a  proliferative  effect  at  the  pre-osteoblast  stage  of 
differentiation acting on AT1R
Addition of angiotensin II to the differentiation media increase proliferation of undifferentiated (white 
bars) and partially differentiated (black bars) cells (A). This effect can be reversed by the addition of 
losartan [10-7M], whereas addition of PD123,319 [10-7M] does not affect proliferation (B)
15.4  -  AT1R  inhibition  blocks  SMAD-mediated  induction  of 
proliferation
In order to identifies  what is  the molecular  mechanism activated by 
AT1R  stimulation,  we  evaluated  if  the  reduction  of  MSCs  and  pre-
osteoblast proliferation was due to an effect of  AT1R inhibition on the 
TGF-ß pathway.  Infact,  recent  evidences  linked  AT1R  blockade  with 
inhibition of TGF-ß pathways in different cell  types. We analyzed the 
level  of  phosphorylated  SMAD2  and  3  (p-SMAD2/3)  as  downstream 
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effectors of TGF-ß and phosphorylated SMAD1, 5 and 8 (pSMAD1/5/8) 
as downstream effectors of BMPs, during the differentiation in presence 
or absence of losartan. In presence of losartan we observe a significant 
decrease of p-SMAD2/3 compared to control cells, indicating a reduction 
in TGF-ß signaling. The reduction is specific for this pathway since the 
complex SMAD1/5/8 is not affected by the losartan treatment. This data 
confirm  that  AT1R  inhibition  induces  an  over-stimulation  of  TGF-ß 
pathway effectors during osteogenic differentiation. 
Figure 38: AT1R inhibitors decrease the phosphorilation of the protein SMAD2/3
Addition of losartan [10-7M] significantly decreased p-SMAD2/3. The reduction is specific for this 
pathway since the complex SMAD1/5/8 is not affected by the treatment. 
15.5  -  Effect  of  angiotensin  receptor  1  inhibitors  on  TGF-ß 
expression 
Recent evidences suggest that the AT1R-mediated induction of TGF-ß 
pathway  may  be  transcriptionally  mediated.  At  this  purpose  we 
performed a Real-Time PCR experiment to evaluate the presence and 
the  possible  variations  of  TGF-ß transcript  levels.  We  observed  a 
reduction of TGF-ß transcription in W20-17 cells treated with osteogenic 
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medium  in  presence  of  losartan.  Even  in  absence  of  osteogenic 
conditions,  TGF-ß transcription  is  induced  by  Ang-II  treatment;  this 
induction  is  specifically  reversed  by  losartan.  TGF-ß receptors  levels 
were identical in any of the previously mentioned conditions.
Figure 39: Expression analysis of TGF-β in angiotensin and losartan treated cells
Expression  profiles  of  TGF-β  in  cells  treated  with  osteogenic  differentiation  medium  (A)  and 
angiotensin  [10-6M] (B).  In  both  case  the  addition  of  losartan  [10-7M] is  able  to  reduce  the 
expression of TGF-β.
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15.6 - Effect of angiotensin receptor inhibitor on mesenchymal 
differentiation
In order to identify the cell fate of the AT1R inhibited cells, we evaluated 
the adipogenic differentiation of cells in presence or absence of losartan 
in  the  osteogenic  medium.  This  medium  contains  beta-
glycerophosphate  and  ascorbic  acid  that  are  specific  for  osteoblast 
differentiation protocols but also dexamethasone that is present also in 
adipogenic medium. Cells treated with losartan in osteogenic medium 
showed a higher amount of adipocytes compared to cells treated with 
only  osteogenic  medium when  stained  with  oil  red-O.  On  the  other 
hand,  addition of  PD123,319 did not  produce any significant  change 
compared to cells treated with only osteogenic medium.
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Figure 40: Inhibition of angiotensin receptor I during the osteoblast differentiation increase 
the presence of adipocyte
Oil  Red  staining  of  cell  treated  with  osteogenic  medium  in  presence  of  angiotensin  receptor 
inhibitors Losartan [10-7M] and PD123,319 [10-7M] (A). Quantification of Oil Red staining of treated 
cells (B).
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DISCUSSION
16 -  shRNA-mediated screening for the identification 
of genes relevant for osteoblast differentiation
16.1 - Set up
The first challenging of this study was to identifies the components and 
the methods to perform the screening. We have decided to apply RNA-
interference technique in a screening approach to investigate on new 
possible  genes  involved  in  osteogenic  differentiation  for  two  main 
reasons: the first consisted in a long-term interest of our laboratory in 
osteoblast differentiation and bone formation and the second was the 
availability of a mouse library of short interfering RNA.
An important boost to begin with our study came from the success of 
RNA approach in another line of research in our research group, with 
the  same  mouse  shRNA  library.  In  the  above-mentioned  a  gene 
essential for the maintenance of stemness embryonic stem cells (Esc) 
was  identified  evaluating  the  effects  of  the  shRNAs  on  the  neural 
differentiation of ESc (Parisi et al., 2009).
We  decided  to  evaluate  osteogenic  differentiation  of  murine 
Mesenchymal  Stem Cells  (mMSC); therefore we chose a specific  cell 
line, a method to differentiate these cells into osteoblasts and a system 
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to detect osteogenic differentiation. Finally, we have adapted all these 
components to perform experiments as high-throughput screening.
We decided to use W20-17 among different types of MSC-derived cell 
lines since they are able to differentiate into osteoblasts; furthermore, 
this  cell  line  was  previously  used  by  other  authors  to  perform 
osteogenic differentiation experiments (Blum et al., 2001; Kempen et 
al., 2008). In order to differentiate W20-17 cells we used osteogenic 
medium (or D.A.G. medium): this medium consist in DMEM with 10% 
fetal bovine serum supplemented with dexametasone, ascorbic acid 2P 
and β-glicerophospate. 
Dexametasone is a glucocorticoid agonist capable to act on responsive 
promoters of transcription factors necessary for MSCs commitment for 
osteogenic lineage. Ascorbic acid-2P promotes the extracellular matrix 
formation and the maturation of all the types of collagens; furthermore, 
it  induces  the  activity  of  plasma  membrane-associated  ALP  in 
osteoprogenitors.  β-glicerophospate  promotes  mineralization  since 
phosphate  groups  are  incorporated  into  idroxiapatite  crystals  of  the 
matrix.
Finally, we chose Alizarin Red S staining for osteogenic differentiation 
detection because it was largely described and used in literature and 
gave solid and reproducible results in our hands.
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16.2 - Experimental approach validation 
After the choice of all the components and methods, we had to establish 
and test the experimental conditions to adopt. This point was crucial to 
execute a reliable process to carry out the high-throughput screening of 
our assay with the library of shRNA constructs.  
We  described  experimental  approach  in  the  results:  essentially  it 
implicates plating of the cells in 96-well microplates, transfection of the 
shRNA plasmids of the library, antibiotic treatment for 3 days in order to 
enrich for  cell  population that incorporated the plasmids and, finally, 
osteogenic  differentiation  protocol.  After  the  above-mentioned 
optimization, we had to test the functionality of the shRNA plasmids for 
our  purpose and,  above all,  the  ability  of  our  system to  detect  the 
osteogenic differentiation impairment by shRNA plasmids acting against 
candidate genes. We therefore performed the test that we described in 
the  section  12.4  of  the  results,  in  which  we  chose  shRNA plasmids 
interfering with genes whose role in osteogenic differentiation had been 
largely described in literature. 
We obtained different grades of osteogenic differentiation impairment 
with these shRNA plasmids and this probably depended upon two main 
reasons: the first reason was that not all the constructs in the library 
are able to silence genes with the same efficiency; the second consisted 
in the different grade of involvement in the osteogenic differentiation 
process of the genes selected.
The most important outcome from these preliminary experiments was 
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the demonstration that using our experimental approach was possible to 
identify  genes  involved  in  osteogenic  differentiation  process  and 
therefore we were able to proceed with the screening.
16.3 - Implementation of the screening
Performing  of  the  screening  was  probably  the  most  relevant 
commitment of this study. We chose the mouse shRNA library because 
of the availability of murine mesenchymal stem cells-derived cell lines 
and  the  prospective  to  work  with  a  mouse  model  for  the  best 
candidates.
The  mouse  shRNA  library  is  composed  of  66,313  shRNA  constructs 
corresponding to 699 plates; we were able to screen 1/7 of the library 
corresponding to 100 plates and about 10,000 constructs. A number of 
library plates contains genes whose function is unknown, we have tried 
to reduce the presence of  these plates,  in  order  to screen a higher 
percentage of known murine genes. So, even though we screened 1/7 
of the total number of genes, we were able to screen about 1/3 of all 
the known genes in mouse. Nonetheless, we equally screened genes 
whose function is still unknown and, in fact, we selected some of these 
genes among our candidates. 
Once  performed  part  of  the  screening  described  in  this  study,  we 
collected  all  the  data  and  we  chose  a  number  of  candidate  genes 
establishing  our  choice  on  the  basis  of  results  from  Alizarin  Red  S 
staining and its quantitation. 
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As we mentioned in the section 13.1 of   the results,  we found 650 
candidate genes corresponding to 6.5% of  the screened genes.  This 
number of candidate genes may seem excessive. A possible explanation 
is that among the candidate genes are included genes whose function is 
essential  for cell  survival,  independently from their role in osteoblast 
differentiation:  therefore,  the final  effect  is  impairment  of  osteoblast 
differentiation even though they are not implicated specifically in this 
process.
After individuation of candidate genes we performed a Gene Ontology 
classification: our candidates were subdivided in different groups on the 
basis of their specific function or the process in which they are involved 
(Carmona-Saez et al., 2007). Most of our candidates are represented by 
genes with unknown function; this was a very interesting results for two 
main reasons: they were about the 30% on the total number of the 
candidates and genes whose function is still unknown are a challenging 
subject to investigate. As regards the rest of the candidates with known 
functions,  it  was  interesting  to  find  a  consistent  number  of  genes 
belonging to the apoptosis  pathway (Glynn Denis  et  al.,  2003).  This 
result validated our experimental approach: in fact, genes belonging to 
the same pathway, when induced in a process,  should be almost all 
positive in a screening. Furthermore, involvement of genes belonging to 
the apoptosis pathway in our study once more validated our screening 
system  since  some  genes  of  apoptosis  pathway,  such  as  several 
caspases,  had  previously  been  demonstrated  to  be  involved  in 
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osteoblast differentiation (Mogi and Togari, 2003).
17 - ObI-1 candidate gene
The effect of ObI-1 gene silencing in osteogenic differentiation was clear 
and therefore we focused our attention on this candidate. Furthermore, 
we found other constructs of the library that interfere with ObI-1 gene 
and,  therefore,  we could  perform silencing  confirmation  experiments 
with three different constructs: this represents a specificity control for 
the  RNA  interference  technique.  In  fact,  in  RNA-interference 
experiments a molecule can cause off-target effects, independently by 
its  activity  on the putative mRNA target; obtaining the same effects 
with  other  RNA molecules  interfering with  the  same gene,  we could 
exclude off-target effects. 
We, therefore, proceeded with an in-silico analysis, particularly required 
for genes with unknown function. Using Ensembl database we found two 
different transcripts for ObI-1 gene and, above all, we identified KRAB 
and zinc-finger functional  domains in the corresponding protein.  This 
results led us to hypothesize that this gene belongs to the family of the 
transcription factors with a KRAB domain (Urrutia, 2003). To confirm 
this hypothesis we also performed immunofluorescence experiments to 
search for the sub-cellular localization of ObI-1. With these experiments 
we demonstrated the nuclear localization of ObI-1, reinforcing the idea 
that this gene may be a transcription factor.   
Proceeding with the bioinformatic analysis, we demonstrated a possible 
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conservation of this gene: in fact we found 14 orthologues in several 
species. It was interesting to find orthologues in Human with different 
levels of homology with the mouse gene. The better value of homology 
was about 46% for one of these orthologues: it was relevant to note 
that homology between the sequences occurs in the functional domains 
of the relative proteins.   
Expression analysis of ObI-1 in tissues was investigated with both in-
silico analysis and Real-Time PCR experiments after RNA extraction from 
different  tissues  in  mouse.  In-silico  analysis  was  performed  by  EST 
profile research on UniGene database of NCBI. An EST profiles can give 
an approximate gene expression pattern of a gene in different tissues 
since  ESTs  (Expressed  Sequence  Tag)  are  short  fragments  of 
transcripted DNA sequenced by cDNA obtained after retrotranscription 
of longer mRNA. This analysis showed the presence of ObI-1 in several 
tissues including bone marrow. Our  analysis  performed by Real-time 
PCR  revealed  a  different  distribution  of  ObI-1  gene  in  the  tissues 
considered. We looked for the expression in bone, lung, heart, kidney, 
testis, liver, spleen and brain. We found a large amount of ObI-1 gene in 
lung,  while  no expression of  ObI-1 was found in  this  organ by EST 
profile  analysis.  Data  regarding  other  organs  were  different.  Most 
relevant result consisted in the expression of ObI-1 in bone. Concerning 
the inconsistencies between the two analyses is important to note that 
EST profile evaluation can be largely inconsistent: EST sequences are, 
in fact, not always correct since their sequencing is automated in only 
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one direction and in a non-overlapping manner.
After analysis in tissues, we also performed expression analysis in W20-
17 cells to search for the presence of ObI-1 gene in our system. We 
analyzed  the  expression  of  ObI-1  transcripts  during  the  osteogenic 
differentiation and we detected an increase for the long form during the 
process respect to time 0 and very low levels of the short form during 
all  the  differentiation.  Considering  this  analysis,  we  hypothesized  a 
possible role of ObI-1 gene in osteogenic differentiation of W20-17 since 
its transcript increase since the day 4 of differentiation and remain high 
during all the process. Furthermore, after this experiments, we did not 
consider anymore the short form since its levels were extremely low. 
In order to complete expression analysis in cells, we also performed 
experiments in primary mMSCs isolated from mouse in our laboratory 
(Esposito et  al.,  2009). Analysis  in primary cells  was very important 
because  a  cell  line,  such  as  W20-17,  may  not  exactly  reproduce  a 
physiological  cellular  environment.  On  the  other  hand,  primary  cells 
better reproduce the biochemical activities observed in-vivo: therefore, 
we decided to proceed with the analysis in these cells. 
Expression of ObI-1 gene during osteogenic differentiation of mMSCs 
was  comparable  to  the  data  obtained  in  W20-17  cells.  This  further 
confirmed  a  role  of  our  candidate  in  osteogenic  differentiation. 
Furthermore, we also performed the expression analysis during MSCs 
adipogenic differentiation: in this case levels of the transcript did not 
increase during the process, but rather they appear even lower at the 
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end of the differentiation compared to day 0. This latter result led us to 
consider  a  possible  specific  role  of  ObI-1  gene  in  the  osteogenic 
differentiation of MSC considering the multipotency of these cells. 
18 – Angiotensin Receptor 1 candidate gene
Regarding AT1R, we demonstrated the involvement of angiotensin in 
pre-osteoblast proliferation and how this process is necessary for a 
correct  osteoblast  development.  Moreover,  we  were  able  to 
demonstrate that angiotensin stimulates TGF-β signaling while has no 
effect on BMPs signaling. Recent studies confirmed the presence of 
RAS system locally in bone: in fact, it has been shown that activation 
of the RAS induces osteoporosis and this effect is independent from 
hypertension (Asaba Y  et  al.,  2009).  The osteoporosis  is  probably 
caused by the Ang-II  mediated increase of  expression of  receptor 
activator of NF-kB ligand (RANKL) in osteoblasts; RANKL secretion 
induces  osteoclasts  proliferation  with  a  pro-osteoporotic  effect 
(Shimizu H et al., 2008). However, the relative role of AT1R and AT2R 
in the induction of osteoporosis appears to be controversial since Izu 
et al. found that AT2R blockade prevents osteoporosis (Izu Y et al, 
2009),  whereas  Shimizu  et  al.  found  that  RANKL  increase  was 
mediated by AT1R (Shimizu H et al., 2008). In our studies, the most 
relevant result in our screening was found the same effects with two 
indipendent  constructs  of  the  library.  This  result  was  relevant  to 
demonstrate  the  specificity  of  the  action  of  AT1R  gene  on  the 
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osteogenic differentiation process. Following the first results from the 
screening,  we repeated AT1R silencing experiments  and confirmed 
osteogenic differentiation impairment. The use of specific angiotensin 
receptors  inhibitors  was  once  more  an  important  result  to 
demonstrate  the  specificity  of  RNA  interference  experiment.  The 
expression profile of AT1R suggested that could have a role from the 
first phase of differentiation. This is, also, confirmed by analyzing the 
role of AT1R in each phase of differentiation. This preliminary data led 
us  to  investigate  a  possible  role  of  angiotensin  receptor  1  in 
proliferation that is confirmed by adding angiotensin II recombinant 
protein to the medium. We had the most significant results when the 
angiotensin II is added to cell that are differentiating. This is probably 
due to the increase of AT1R transcript in early stage of differentiation 
when the cells start to differentiate. Several  studies correlates the 
TGF-β signaling to osteblast proliferation. TGF-β has been reported to 
stimulate proliferation and early differentiation, while inhibits terminal 
differentiation. We found that using specific  angiotensin receptor 1 
inhibitors,  such  as  losartan,  is  possible  to  modify  the  level  of 
phosphorilation of smad2/3 that is  effectors of TGF-β signaling.  In 
order to indicate the mechanism of Ang II-mediated increase of TGF-
β signaling we evaluated transcription of TGF-beta and its receptors. 
We  found  that  increased  levels  of  Ang  II  appears  to  induce 
transcription of TGF-beta.
In  our  study,  we  did  not  address  any  role  to  AT2R  during  the 
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osteogenic differentiation but we can not exclude that this receptor 
could be involved. In fact, in our in vitro model of osteoblastogenesis, 
we  did  not  observe  a  reduction  of  mineralization  after 
pharmacological inhibition of AT2R even if we found an increase of 
AT2R transcript in the late phase of differentiation. Moreover, recent 
studies show how a treatment with AT2 receptor blocker significantly 
enhanced the levels of bone mass (Izu Y et al, 2009). This is probably 
due  to  the  fact  that  our  experimental  design  is  optimized  to 
individuate  gene  whose  silencing  is  able  to  impair,  and  not  to 
improve, the osteoblast differentiation.
We  can  therefore  conclude  from this  study  that  AT1R  stimulation 
increase  pre-osteoblast  proliferation  through  TGF-beta  canonical 
SMAD-signaling pathway. In addition, AT1R inhibition may be proved 
an  interesting  approach  to  diseases  due  MSCs  or  pre-osteoblasts 
hyperproliferation.
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CONCLUSIONS 
In this work we have described set up and implementation of a shRNA-
mediated  screening  aimed  at  the  identification  of  genes  involved  in 
osteoblast  differentiation.  Prior  this  study,  this  mouse  shRNA library 
present in our institute was previously used to perform a screening to 
find genes involved in neural differentiation of ESCs. With our work we 
demonstrated versatility of this library and therefore the possibility to 
adapt this tool for different types of assay. In fact, the system that we 
have developed, allowed us to perform a screening of mouse genes to 
identify those involved in osteoblast differentiation. The high-through 
put  system  can  be  adapted  to  pharmacological  as  well  as  other 
screenings to identify modulator of osteoblastic differentiation. 
A  future  perspective  of  this  study  consists  in  completing  the 
characterization  of  the  identified  genes  by  morphological  analysis  in 
cells and in vivo data: in fact, their identification with the screening and 
the following analysis in the cellular system represents an interesting 
starting  points  to  further  investigate  on  their  role  in  osteoblast 
differentiation and eventually to individuate new target for bone related 
pathologies in vivo. 
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